PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21443709-2	2011	The aim of this study was to determine relationship between cagA genotype and metronidazole resistant strains of H. pylori in Thai FD patients.	Metronidazole	78-91	S100 calcium binding protein A8	Homo sapiens	60-64
21377771-2	2011	The results showed that out of fifteen compounds, four were found to be more active against the Entamoeba histolytica; while one compound was moderatively active compared to the standard drug metronidazole (IC50=1.46 muM).	Metronidazole	192-205	latexin	Homo sapiens	217-220
21443709-13	2011	In EPS patients, presence of cagA 2a gene was significantly higher in metronidazole resistant than metronidazole sensitive strains (100% vs 74.1%; OR = 4.8, 95% CI = 1.2-26.8, P = 0.01).	Metronidazole	70-83	S100 calcium binding protein A8	Homo sapiens	29-33
21443709-13	2011	In EPS patients, presence of cagA 2a gene was significantly higher in metronidazole resistant than metronidazole sensitive strains (100% vs 74.1%; OR = 4.8, 95% CI = 1.2-26.8, P = 0.01).	Metronidazole	99-112	S100 calcium binding protein A8	Homo sapiens	29-33
21443709-16	2011	In EPS patients, cagA 2a gene might be related to metronidazole resistant strains of H. pylori infection in Thailand.	Metronidazole	50-63	S100 calcium binding protein A8	Homo sapiens	17-21
21087863-1	2011	With the aim to develop new potential (99m)Tc-radiopharmaceuticals for imaging hypoxia based on the formation of Tc-nitrido complexes, two novel dithiocarbamate containing metronidazole derivatives (L1 and L2) have been prepared and characterised.	Metronidazole	172-185	L1 cell adhesion molecule	Mus musculus	199-208
21422854-2	2011	METHODS: This was a secondary analysis of a randomized trial of metronidazole and erythromycin for the prevention of preterm birth among women with a positive fetal fibronectin test.	Metronidazole	64-77	fibronectin 1	Homo sapiens	165-176
20657580-2	2010	Metronidazole, a bactericide, or N-acetylcysteine, a precursor of sulfide-buffering glutathione, substantially prolonged the lifespan of Ethe1-deficient mice, with the combined treatment being additive.	Metronidazole	0-13	ethylmalonic encephalopathy 1	Mus musculus	137-142
20846902-0	2010	Spectroscopic investigation on assisted sonocatalytic damage of bovine serum albumin (BSA) by metronidazole (MTZ) under ultrasonic irradiation combined with nano-sized ZnO.	Metronidazole	94-107	albumin	Homo sapiens	71-84
20846902-0	2010	Spectroscopic investigation on assisted sonocatalytic damage of bovine serum albumin (BSA) by metronidazole (MTZ) under ultrasonic irradiation combined with nano-sized ZnO.	Metronidazole	109-112	albumin	Homo sapiens	71-84
21266816-5	2011	METHODS: 48 patients with steroid-dependent UC were recruited for a 2-week treatment with amoxicillin, tetracycline, and metronidazole (ATM).	Metronidazole	121-134	ATM serine/threonine kinase	Homo sapiens	136-139
20306185-3	2010	We have assessed the possible inhibitory effects of metronidazole on P-gp-mediated drug disposition in healthy subjects using fexofenadine as a P-gp substrate.	Metronidazole	52-65	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
20547640-3	2010	We report here the case of a 2-year-old child with relapsing CDI caused by the epidemic strain BI/NAP1/O27 that was refractory to Saccharomyces boulardii and Lactobacillus rhamnosus GG probiotics and to intensive therapy with traditional (metronidazole, vancomycin) and experimental (rifaximin, nitazoxanide) antibiotics despite its apparent antimicrobial-susceptible phenotype.	Metronidazole	239-252	nucleosome assembly protein 1 like 1	Homo sapiens	98-102
20376628-13	2010	CONCLUSION: The results suggest that the CYP2C19 genotype contrary to MDR1 and IL-1B genotypes may have an impact on the efficacy of H. pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole.	Metronidazole	292-305	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	41-48
20405274-14	2010	CONCLUSIONS: Metronidazole and gentamicin combination is effective on TPN-induced liver injury by the Bcl-2 anti-apoptotic pathway, total anti-apoptotic effect and by decreasing bilirubin levels.	Metronidazole	13-26	BCL-2	Oryctolagus cuniculus	102-107
20093143-3	2010	In our previous work we identified the flavin enzyme thioredoxin reductase as an electron donor to 5-nitroimidazole drugs in T. vaginalis and observed that highly metronidazole-resistant cell lines lack thioredoxin reductase and flavin reductase activities.	Metronidazole	163-176	peroxiredoxin 5	Homo sapiens	53-74
20093143-4	2010	In this study we added the flavin inhibitor diphenyleneiodonium (DPI) to T. vaginalis cultures in order to test our hypothesis that metronidazole reduction is catalyzed by flavin enzymes, e.g. thioredoxin reductase, and intracellular free flavins.	Metronidazole	132-145	peroxiredoxin 5	Homo sapiens	193-214
19957722-2	2009	It is established, that among components of antiulcerous therapy such as omeprazole, clarithromycin and metronidazole inhibit content and activity of MOS enzymes.	Metronidazole	104-117	MOS proto-oncogene, serine/threonine kinase	Rattus norvegicus	150-153
20006932-0	2010	Assisted sonodynamic damage of bovine serum albumin by metronidazole under ultrasonic irradiation combined with photosensitive antitumor drug-Amsacrine.	Metronidazole	55-68	albumin	Homo sapiens	38-51
21294447-15	2010	In conclusion, triple therapy failure was associated with CLR-R. Metronidazole resistance exceeded that of CLR, hence it cannot be substituted for CLR in a triple therapy.	Metronidazole	65-78	doublecortin like kinase 3	Homo sapiens	58-61
19957722-5	2009	In triple therapy with omeprazole, clarithromycin and metronidazole the inhibit effect of preparations to system of MOS is exponentiated and it leads to suppression of mucous cytoprotaction of gastro duodenal zone.	Metronidazole	54-67	MOS proto-oncogene, serine/threonine kinase	Rattus norvegicus	116-119
18048573-1	2007	Recent case reports suggest that addition of high-dose metronidazole might be associated with elevated plasma concentrations of substrates of cytochrome P450 (CYP) 3A.	Metronidazole	55-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-166
18843215-3	2008	We also report Capnocytophaga spp naturally resistant to metronidazole, this being the cause of inefficacy of this drug usually included in empiric chemotherapy of cerebral abscess.	Metronidazole	57-70	histocompatibility minor 13	Homo sapiens	30-33
18182250-8	2008	MTZ also induced a significant decrease in delayed-type hypersensitivity (DTH) reaction, phagocytic activity (assessed by phagocytic capacity and phagocytic index) as well as TNF-alpha secretion by peritoneal macrophages.	Metronidazole	0-3	tumor necrosis factor	Homo sapiens	175-184
19155507-8	2009	ApoE(+/-) mice injected with DPG3 or metronidazole showed significantly fewer atheromatous lesions in the proximal aorta and the aortic tree compared with ApoE(+/-) mice injected with wild-type P. gingivalis for either diet condition.	Metronidazole	37-50	apolipoprotein E	Mus musculus	0-4
19155507-9	2009	Serum amyloid A levels were significantly lower in ApoE(+/-) mice that received either DPG3 or metronidazole before P. gingivalis than from ApoE(+/-) mice that received P. gingivalis alone.	Metronidazole	95-108	apolipoprotein E	Mus musculus	51-55
18279557-10	2008	Both EC-M17 and metronidazole reduced colonic IL-12, IL-6, IL-1beta and interferon-gamma.	Metronidazole	16-29	interleukin 6	Mus musculus	53-57
18279557-10	2008	Both EC-M17 and metronidazole reduced colonic IL-12, IL-6, IL-1beta and interferon-gamma.	Metronidazole	16-29	interleukin 1 beta	Mus musculus	59-67
18279557-10	2008	Both EC-M17 and metronidazole reduced colonic IL-12, IL-6, IL-1beta and interferon-gamma.	Metronidazole	16-29	interferon gamma	Mus musculus	72-88
19088952-7	2008	Alpha2-macroglobulin was significantly reduced for scaling and root planing and metronidazole after 3 and 6 months (P< .001).	Metronidazole	80-93	alpha-2-macroglobulin	Homo sapiens	0-20
17374625-0	2007	Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway?	Metronidazole	5-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38
18004483-11	2007	Metronidazole lightly inhibited the proliferation and ALP activity of HPLFs, its cytotoxicity was at 1 grade, with rehabilitation rate from 32% to 85%.	Metronidazole	0-13	ATHS	Homo sapiens	54-57
17520506-5	2007	After changing the antibiotics to ceftriaxon and metronidazole, acute cholangitis being suspected, the fever subsided immediately and the CRP level decreased.	Metronidazole	49-62	C-reactive protein	Homo sapiens	138-141
17336015-9	2007	The evolution was favorable after itavenous antibiotherapy combining ceftriaxone(DCI) (2 g/j), metronidazole(DCI) (1 g/j), and ciprofloxacin(DCI).	Metronidazole	95-108	enoyl-CoA delta isomerase 1	Homo sapiens	109-112
17336015-9	2007	The evolution was favorable after itavenous antibiotherapy combining ceftriaxone(DCI) (2 g/j), metronidazole(DCI) (1 g/j), and ciprofloxacin(DCI).	Metronidazole	95-108	enoyl-CoA delta isomerase 1	Homo sapiens	109-112
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	50-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	50-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-147
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	98-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	98-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-147
17374625-8	2007	DATA SYNTHESIS: Elevated plasma concentrations and toxicities have been reported for a number of CYP3A substrates including amiodarone, carbamazepine, quinidine, tacrolimus, and cyclosporine when administered with metronidazole.	Metronidazole	214-227	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102
17374625-9	2007	This has led to the widespread belief that metronidazole is a significant inhibitor of CYP3A4.	Metronidazole	43-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-93
17374625-11	2007	CONCLUSIONS: Drug interactions between metronidazole and certain CYP3A substrates do not appear to result from CYP3A4/5 inhibition by metronidazole.	Metronidazole	39-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-70
17374625-12	2007	Until any mechanism is identified by which metronidazole alters the disposition of certain CYP3A substrates, drug interactions with this agent should be assessed on a case-by-case basis, taking into account the safety index of the coadministered drug and the availability of equally effective substitutes for either metronidazole or the drug with which it putatively interacts.	Metronidazole	43-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
16907946-0	2006	A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study.	Metronidazole	33-46	fibronectin 1	Homo sapiens	126-137
18197807-5	2007	Antigen-specific T-cell responses were greatest in the group receiving the CEA-TRICOM vaccines and were shown to correlate with survival.	Metronidazole	79-85	CEA cell adhesion molecule 3	Homo sapiens	75-78
17142781-6	2006	Prophylactic or therapeutic administration of ciprofloxacin and/or metronidazole ameliorated ileal immunopathology and reduced intestinal NO and IFN-gamma levels.	Metronidazole	67-80	interferon gamma	Mus musculus	145-154
17153694-14	2006	Both of SLPI & RNI levels returned to normal levels in 93.4% & 80% of symptomatic patients respectively one week after metronidazole therapeutic course.	Metronidazole	127-140	secretory leukocyte peptidase inhibitor	Homo sapiens	8-12
16827775-0	2006	A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study by Shennan et al.	Metronidazole	33-46	fibronectin 1	Homo sapiens	126-137
16827776-0	2006	A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET study.	Metronidazole	33-46	fibronectin 1	Homo sapiens	126-137
15990986-10	2005	The prevalence of ESBL-producers increased significantly during therapy in OASIS II among 193 ceftriaxone/metronidazole recipients (from 4 [2.1%] to 18 [9.3%]) (p<0.001), whereas no ertapenem recipient was colonized with an ESBL-producer at the end of therapy in either study.	Metronidazole	106-119	cAMP responsive element binding protein 3 like 1	Homo sapiens	75-80
16706246-0	2006	A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3).	Metronidazole	16-29	olfactory receptor family 6 subfamily C member 2	Homo sapiens	68-73
16398774-0	2006	A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study.	Metronidazole	33-46	fibronectin 1	Homo sapiens	126-137
16398774-1	2006	OBJECTIVE: To determine whether metronidazole reduces early preterm labour in asymptomatic women with positive vaginal fetal fibronectin (fFN) in the second trimester of pregnancy.	Metronidazole	32-45	fibronectin 1	Homo sapiens	125-136
16151741-18	2005	Two weeks after metronidazole treatment, serum concentration of GOT, GPT and NH3 were significantly increased in comparison with those treated with silymarin.	Metronidazole	16-29	glutamic--pyruvic transaminase	Canis lupus familiaris	69-72
16151741-22	2005	The numbers of WBC and RBC did show significant differences in the dogs treated with metronidazole, while MCV, MCH were significant by different between silymarin and metronidazole-treated dogs.	Metronidazole	167-180	pro-melanin concentrating hormone	Canis lupus familiaris	111-114
16388032-8	2006	Post-treatment resistance to metronidazole was common (81.6%) and that to clarithromycin was considerable (36%).	Metronidazole	29-42	solute carrier family 35 member G1	Homo sapiens	0-4
15565569-7	2004	After 36 months, serum aminotransferases gamma-glutamyltransferase, and alkaline phosphatase (ALP) decreased markedly in both groups, serum ALP more significantly in the UDCA/MTZ group (-337 +/- 54 U/L, P < .05) compared with the UDCA/placebo group.	Metronidazole	175-178	alkaline phosphatase, placental	Homo sapiens	140-143
15855244-8	2005	The possible mechanism may be related to metronidazole"s weak inhibition of CYP3A4 and, possibly, P-glycoprotein.	Metronidazole	41-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
15855244-8	2005	The possible mechanism may be related to metronidazole"s weak inhibition of CYP3A4 and, possibly, P-glycoprotein.	Metronidazole	41-54	ATP binding cassette subfamily B member 1	Homo sapiens	98-112
15756055-7	2005	Tylosin and metronidazole significantly lowered macroscopic lesion score, reduced colon weight, the severity of histologic lesions and myeloperoxidase activity; budesonide did not significantly change the parameters of colonic inflammation.	Metronidazole	12-25	myeloperoxidase	Rattus norvegicus	135-150
15728145-9	2005	When this metronidazole time course was simulated in vitro, the time to 99.9% kill ranged from 1.0 to 1.4 h for BF125 and from 1.8 to 3.5 h for BF1, while the eradication time ranged from 1.7 to 2.5 h and from 3.4 to 6.5 h, respectively.	Metronidazole	10-23	forkhead box G1	Homo sapiens	112-115
15613691-11	2005	CONCLUSION: We demonstrated that the CEA-TRICOM vaccines are safe and can generate significant CEA-specific immune responses, and they seem to have clinical benefit in some patients with advanced cancer.	Metronidazole	41-47	CEA cell adhesion molecule 3	Homo sapiens	37-40
15613691-11	2005	CONCLUSION: We demonstrated that the CEA-TRICOM vaccines are safe and can generate significant CEA-specific immune responses, and they seem to have clinical benefit in some patients with advanced cancer.	Metronidazole	41-47	CEA cell adhesion molecule 3	Homo sapiens	95-98
15565569-11	2004	In conclusion, combining MTZ with UDCA in PSC improved serum ALP levels and New Mayo Risk Score, but no statistically significant effect on disease progression as assessed via liver histology or ERCP was seen.	Metronidazole	25-28	alkaline phosphatase, placental	Homo sapiens	61-64
15150334-5	2004	The success of regimes consisting of a proton pump inhibitor, amoxycillin and metronidazole (PPI/A/M) has also been evaluated in patients found positive on serological testing in primary care using urea breath testing.	Metronidazole	78-91	peptidylprolyl isomerase A	Homo sapiens	93-100
15338063-1	2004	OBJECTIVE: In a recently completed randomised clinical trial in patients with colorectal cancer resections the combination of the granulocyte-colony stimulating factor (G-CSF) + cefuroxime/ metronidazole (cef/met) was superior to ofloxacin/metronidazole (ofl/met).	Metronidazole	240-253	colony stimulating factor 3	Homo sapiens	130-167
12730879-6	2003	RESULTS: Chronic metronidazole treatment decreases colonic mucosal hsp25 and hsp72 expression, an effect associated with increased susceptibility of mucosal barrier function to C. difficile toxin A. Hsp expression also was increased in YAMC cells incubated with B. fragilis, an effect mediated by lipopolysaccharide and other bacteria-derived factors.	Metronidazole	17-30	heat shock protein 1	Mus musculus	67-72
15125692-6	2004	The deleterious effects of metronidazole on reproductive organ weights might be due to a decrease in testosterone level after 2 weeks, and 1 and 2 months from the onset of treatment.	Metronidazole	27-40	WD repeat and HMG-box DNA binding protein 1	Mus musculus	135-146
14633725-5	2003	Vaccination of mice with MVA-CEA/TRICOM induced potent CD4+ and CD8+ T-cell responses specific for CEA.	Metronidazole	33-39	carcinoembryonic antigen gene family	Mus musculus	99-102
14633725-7	2003	The use of MVA-CEA/TRICOM in a diversified prime and boost vaccine regimen with rF-CEA/TRICOM, however, induced significantly greater levels of both CD4+ and CD8+ T-cell responses specific for CEA than that seen with rV-CEA/TRICOM prime and rF-CEA/TRICOM boost.	Metronidazole	19-25	CEA cell adhesion molecule 5	Homo sapiens	83-86
14633725-7	2003	The use of MVA-CEA/TRICOM in a diversified prime and boost vaccine regimen with rF-CEA/TRICOM, however, induced significantly greater levels of both CD4+ and CD8+ T-cell responses specific for CEA than that seen with rV-CEA/TRICOM prime and rF-CEA/TRICOM boost.	Metronidazole	19-25	CEA cell adhesion molecule 5	Homo sapiens	83-86
14633725-7	2003	The use of MVA-CEA/TRICOM in a diversified prime and boost vaccine regimen with rF-CEA/TRICOM, however, induced significantly greater levels of both CD4+ and CD8+ T-cell responses specific for CEA than that seen with rV-CEA/TRICOM prime and rF-CEA/TRICOM boost.	Metronidazole	19-25	CEA cell adhesion molecule 5	Homo sapiens	83-86
14633725-7	2003	The use of MVA-CEA/TRICOM in a diversified prime and boost vaccine regimen with rF-CEA/TRICOM, however, induced significantly greater levels of both CD4+ and CD8+ T-cell responses specific for CEA than that seen with rV-CEA/TRICOM prime and rF-CEA/TRICOM boost.	Metronidazole	19-25	CEA cell adhesion molecule 5	Homo sapiens	83-86
12738742-15	2003	RESULTS: The CEA/TRICOM vaccination regimen induced a therapeutic antitumor response as measured by increased survival, which was due largely to induced T-cell responses (both CD4(+) and CD8(+)) as determined by selective T-cell subset depletion.	Metronidazole	17-23	CD4 antigen	Mus musculus	176-179
12730879-6	2003	RESULTS: Chronic metronidazole treatment decreases colonic mucosal hsp25 and hsp72 expression, an effect associated with increased susceptibility of mucosal barrier function to C. difficile toxin A. Hsp expression also was increased in YAMC cells incubated with B. fragilis, an effect mediated by lipopolysaccharide and other bacteria-derived factors.	Metronidazole	17-30	heat shock protein 1A	Mus musculus	77-82
12738139-0	2003	Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women.	Metronidazole	29-42	fibronectin 1	Homo sapiens	110-121
12724036-2	2003	Co-administration of the antibiotics amoxicillin and metronidazole (AMPC-MET) significantly increased the area under the plasma concentration versus time curve (AUC) of PF, whereas it markedly decreased that of PM-I, to 2.6% of the normal AUC by administration of a single dose, and less than 1% by a 3-day pretreatment.	Metronidazole	53-66	mannose phosphate isomerase	Rattus norvegicus	211-215
12698306-1	2003	OBJECTIVE: To screen for inhibitory effects of diosmin on cytochrome P(450)-mediated metabolism of metronidazole in healthy volunteers.	Metronidazole	99-112	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-75
12729319-5	2003	RESULTS: Metronidazole plus ciprofloxacin decreased the CRP in seven patients and the IOIBD score in six patients.	Metronidazole	9-22	C-reactive protein	Homo sapiens	56-59
12624780-2	2003	Metronidazole and tinidazole ointments (1) suppressed the late-phase reaction (LPR) of biphasic ear edema in mice sensitized with ovalbumin (OA), (2) suppressed trinitrochlorobenzene-induced inflammatory dermatitis, (3) suppressed the immediate phase reactions and LPR in mice passively sensitized with anti-DNP IgE mAb, and (4) enhanced vascular permeability and the number of scratching reactions, presumably due to itching, in passively sensitized mice.	Metronidazole	0-13	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	130-139
12111578-2	2002	Therefore, this study investigated the effects of frequently used antimicrobial agents (beta-lactams, quinolones gentamicin, vancomycin and metronidazole) on the in-vitro tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production of isolated human peripheral blood mononuclear cells (PBMNC), cultured with or without endotoxin, in comparison with those effects obtained in a whole-blood assay system.	Metronidazole	140-153	tumor necrosis factor	Homo sapiens	171-204
15095923-1	2003	The aim of this study was to compare the influence of antimicrobials (clindamycin, metronidazole and polymyxin B) on the expression of adhesion molecules (VCAM-1, ICAM-1 and E-selectin) on the HMEC-1 cell line stimulated by LPS and enterotoxin of B. fragilis.	Metronidazole	83-96	vascular cell adhesion molecule 1	Homo sapiens	155-161
15095923-1	2003	The aim of this study was to compare the influence of antimicrobials (clindamycin, metronidazole and polymyxin B) on the expression of adhesion molecules (VCAM-1, ICAM-1 and E-selectin) on the HMEC-1 cell line stimulated by LPS and enterotoxin of B. fragilis.	Metronidazole	83-96	intercellular adhesion molecule 1	Homo sapiens	163-169
15095923-1	2003	The aim of this study was to compare the influence of antimicrobials (clindamycin, metronidazole and polymyxin B) on the expression of adhesion molecules (VCAM-1, ICAM-1 and E-selectin) on the HMEC-1 cell line stimulated by LPS and enterotoxin of B. fragilis.	Metronidazole	83-96	selectin E	Homo sapiens	174-184
15095923-6	2003	Clindamycin, metronidazole and polymyxin B supressed the ICAM-1 expression when endothelium was stimulated with B. fragilis LPS and augmented ICAM-1 expression by Tox 1 and Tox 2.	Metronidazole	13-26	intercellular adhesion molecule 1	Homo sapiens	57-63
15095923-6	2003	Clindamycin, metronidazole and polymyxin B supressed the ICAM-1 expression when endothelium was stimulated with B. fragilis LPS and augmented ICAM-1 expression by Tox 1 and Tox 2.	Metronidazole	13-26	intercellular adhesion molecule 1	Homo sapiens	142-148
12165029-9	2002	CONCLUSIONS: In the presence of metronidazole resistance, PPI-B-T-M as a recommended second-line therapy by the Maastricht consensus conference achieved unacceptable low cure rates in our metronidazole pretreated population.	Metronidazole	32-45	peptidylprolyl isomerase B	Homo sapiens	58-63
12165029-9	2002	CONCLUSIONS: In the presence of metronidazole resistance, PPI-B-T-M as a recommended second-line therapy by the Maastricht consensus conference achieved unacceptable low cure rates in our metronidazole pretreated population.	Metronidazole	188-201	peptidylprolyl isomerase B	Homo sapiens	58-63
12121793-1	2002	In this work we present the synthesis and structural and spectroscopic characterization of Cu(II), Co(II) and Zn(II) coordination compounds with the antibiotic metronidazole ([double bond]emni).	Metronidazole	160-173	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-105
12107032-11	2002	Metronidazole inhibited only colonic mucosal high K(M) ALDH and increased intracolonic, but not blood, acetaldehyde levels.	Metronidazole	0-13	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	55-59
12111578-3	2002	In the presence of ciprofloxacin, ofloxacin, gentamicin, vancomycin, and metronidazole, a significant inhibition of the endotoxin-stimulated TNF-alpha production of human peripheral blood mononuclear cells (PBMNC) was found at therapeutic levels.	Metronidazole	73-86	tumor necrosis factor	Homo sapiens	141-150
11996701-6	2002	Resistance to metronidazole and clarythromycin was significantly higher (p 5 0.03 and p < 0.001 respectively) in strains isolated from patients who had received previous treatment.	Metronidazole	14-27	CD40 molecule	Homo sapiens	73-78
11934438-0	2002	Role of P53 functionality in the genotoxicity of metronidazole and its hydroxy metabolite.	Metronidazole	49-62	tumor protein p53	Homo sapiens	8-11
11757405-1	2001	The influence of metronidazole on the level of expression of adhesion molecules ICAM-1, VCAM-1 and E-selectin on the surface of vascular endothelial cells activated with B. fragilis endotoxins and enterotoxin was examined.	Metronidazole	17-30	intercellular adhesion molecule 1	Homo sapiens	80-86
11601665-0	2001	Effects of metronidazole on hepatic CYP3A4 activity.	Metronidazole	11-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
11601665-1	2001	STUDY OBJECTIVE: To evaluate the effect of a short course of oral metronidazole, commonly used for bowel-preparation regimens, on hepatic cytochrome P450 (CYP) 3A4 activity, as measured by the [14C N-methyl]-erythromycin breath test (ERMBT) in healthy volunteers.	Metronidazole	66-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-163
11525565-7	2001	It is a multistage, dose-escalation study that will assess the safety and immunologic effects of CEA-TRICOM in up to 42 patients who have advanced metastatic colorectal cancer.	Metronidazole	101-107	CEA cell adhesion molecule 3	Homo sapiens	97-100
11707060-10	2001	Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.	Metronidazole	0-13	CD5 molecule	Homo sapiens	109-117
11720808-1	2001	The influence of sanazole and metronidazole on cytochrome C (Cyt c(3+)) reduction in the enzyme systems xanthine/xanthine oxidase and NADPH-cytochrome P450 reductase was studied.	Metronidazole	30-43	cytochrome c, somatic	Homo sapiens	47-59
11720808-1	2001	The influence of sanazole and metronidazole on cytochrome C (Cyt c(3+)) reduction in the enzyme systems xanthine/xanthine oxidase and NADPH-cytochrome P450 reductase was studied.	Metronidazole	30-43	cytochrome p450 oxidoreductase	Homo sapiens	134-165
11518914-0	2001	Metronidazole treatment of women with a positive fetal fibronectin test result.	Metronidazole	0-13	fibronectin 1	Homo sapiens	55-66
11349014-4	2001	The recA mutants are sensitive to DNA-damaging agents and show increased susceptibility to metronidazole, the first lead compound active against the dormant M. tuberculosis complex.	Metronidazole	91-104	RAD51 recombinase	Mus musculus	4-8
11757405-1	2001	The influence of metronidazole on the level of expression of adhesion molecules ICAM-1, VCAM-1 and E-selectin on the surface of vascular endothelial cells activated with B. fragilis endotoxins and enterotoxin was examined.	Metronidazole	17-30	vascular cell adhesion molecule 1	Homo sapiens	88-94
11757405-1	2001	The influence of metronidazole on the level of expression of adhesion molecules ICAM-1, VCAM-1 and E-selectin on the surface of vascular endothelial cells activated with B. fragilis endotoxins and enterotoxin was examined.	Metronidazole	17-30	selectin E	Homo sapiens	99-109
11151744-1	2000	OBJECTIVE: Case reports have described elevated concentrations of CYP3A4 substrates (e.g. cyclosporin) during metronidazole treatment.	Metronidazole	110-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
11097307-3	2000	METHODS: We studied the expression of the CLA in peripheral blood T cells from nine subjects with exanthematous reactions induced by beta-lactams (4), phenytoin (2), propyphenazone (1), spiramycin plus metronidazol (1), and captopril plus tiazide (1).	Metronidazole	202-214	selectin P ligand	Homo sapiens	42-45
11151744-2	2000	Therefore, we wanted to study whether metronidazole affects CYP3A4 activity, using midazolam as a model substrate in vitro and in vivo.	Metronidazole	38-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
11000734-11	2000	In the ALM and MLC subgroups (i.e., patients who received metronidazole), the eradication failure rate was significantly higher for patients with MR isolates than for patients with metronidazole-susceptible isolates (47% vs 16%, p < 0.05).	Metronidazole	58-71	modulator of VRAC current 1	Homo sapiens	15-18
9825505-3	1998	After the simultaneous introduction of TNF, gamma-interferon and CIP into the culture medium, the sensitivity of Trichomonas to the action of metronidazole increased 5- to 7-fold.	Metronidazole	142-155	tumor necrosis factor	Homo sapiens	39-42
10704650-1	2000	In this study we examined in 100 patients testing positive for Helicobacter pylori infection whether successful eradication therapy with pantoprazole, clarithromycin, and metronidazole alters fibrinogen and other acute phase response markers.	Metronidazole	171-184	fibrinogen beta chain	Homo sapiens	192-202
10917381-8	2000	A contributing factor in this case may have been the concomitant administration of metronidazole, which inhibits the cytochrome P450 enzyme (CYP3A4) also responsible for the metabolism of quetiapine.	Metronidazole	83-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
10684241-9	1999	Therapy with oral metronidazol for 40 days led to complete recovery from symptoms and normalisation of ACE serum levels.	Metronidazole	18-30	angiotensin I converting enzyme	Homo sapiens	103-106
10746324-5	1999	The quantitative prediction abilities in determining metronidazole and pefloxacin plasma levels of the PLS1 and PLS2 models were tested on spiked plasma samples and good results were obtained (metronidazole, 97.5%, RSD = 4.8%, n = 3; pefloxacin, 100.6%, RSD = 3.6%, n = 3).	Metronidazole	53-66	plastin 1	Homo sapiens	103-107
10746324-5	1999	The quantitative prediction abilities in determining metronidazole and pefloxacin plasma levels of the PLS1 and PLS2 models were tested on spiked plasma samples and good results were obtained (metronidazole, 97.5%, RSD = 4.8%, n = 3; pefloxacin, 100.6%, RSD = 3.6%, n = 3).	Metronidazole	53-66	lymphocyte cytosolic protein 1	Homo sapiens	112-116
10746324-5	1999	The quantitative prediction abilities in determining metronidazole and pefloxacin plasma levels of the PLS1 and PLS2 models were tested on spiked plasma samples and good results were obtained (metronidazole, 97.5%, RSD = 4.8%, n = 3; pefloxacin, 100.6%, RSD = 3.6%, n = 3).	Metronidazole	193-206	plastin 1	Homo sapiens	103-107
10746324-5	1999	The quantitative prediction abilities in determining metronidazole and pefloxacin plasma levels of the PLS1 and PLS2 models were tested on spiked plasma samples and good results were obtained (metronidazole, 97.5%, RSD = 4.8%, n = 3; pefloxacin, 100.6%, RSD = 3.6%, n = 3).	Metronidazole	193-206	lymphocyte cytosolic protein 1	Homo sapiens	112-116
10449953-7	1999	Enhanced cytokine levels, particularly of IL-5, were found in the supernatant of the LTT stimulated with ceftriaxone and metronidazole.	Metronidazole	121-134	interleukin 5	Homo sapiens	42-46
10889327-5	2000	[Pd(2-Acpy-SMDT)C1(2)] and Pd(2-Acpy-SBDT)C1(2)] have shown greater activity, whereas [Pd(2-Acpy-TSC)C1(2)] showed similar activity as metronidazole in vitro.	Metronidazole	135-148	TSC complex subunit 1	Homo sapiens	97-100
10735923-12	2000	In patients treated with LAO, effective treatment was achieved in 87% of metronidazole-susceptible, but only 30% of metronidazole-resistant strains (P < 0.01).	Metronidazole	73-86	interleukin 4 induced 1	Homo sapiens	25-28
10735923-12	2000	In patients treated with LAO, effective treatment was achieved in 87% of metronidazole-susceptible, but only 30% of metronidazole-resistant strains (P < 0.01).	Metronidazole	116-129	interleukin 4 induced 1	Homo sapiens	25-28
10774678-3	1999	Our study indicates that amebic liver abscess is easily treated by appropriate administration of metronidazole even in an old AIDS patient receiving anti-HIV drugs with low CD4 cell counts and high HIV-RNA values.	Metronidazole	97-110	CD4 molecule	Homo sapiens	173-176
10233191-18	1999	Significantly lower cure rates were observed in metronidazole-resistant patients treated with PAM (56% vs. 96%, P = 0.01) or PCM (50% vs. 97%, P = 0.01).	Metronidazole	48-61	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	94-97
9772054-9	1998	The two patients failing RAM treatment had metronidazole-resistant strains before and after treatment.	Metronidazole	43-56	CCDC26 long non-coding RNA	Homo sapiens	25-28
9741020-11	1998	Metronidazole treatment reduced histology score (6.0 +/- 0.5) p < 0.05 and MPO (5.9 +/- 1.6) p < 0.001 in rats with pouches compared with rats with pouches that had no treatment.	Metronidazole	0-13	myeloperoxidase	Rattus norvegicus	78-81
9529499-9	1998	Both continuous metronidazole and aztreonam reduced lung MPO concentration (P < 0.05) and TNF-alpha and IL-1 beta mRNA expression (P < 0.05) compared with those in saline controls.	Metronidazole	16-29	myeloperoxidase	Mus musculus	57-60
9663723-18	1998	In patients with pre-treatment metronidazole resistance, the eradication rate was 75% in group OCT and 33% in group CT. Post-treatment resistance to clarithromycin was induced in 28.5% of the failures in group C, but in none of group OC.	Metronidazole	31-44	plexin A2	Homo sapiens	95-98
9529499-9	1998	Both continuous metronidazole and aztreonam reduced lung MPO concentration (P < 0.05) and TNF-alpha and IL-1 beta mRNA expression (P < 0.05) compared with those in saline controls.	Metronidazole	16-29	tumor necrosis factor	Mus musculus	93-102
9529499-9	1998	Both continuous metronidazole and aztreonam reduced lung MPO concentration (P < 0.05) and TNF-alpha and IL-1 beta mRNA expression (P < 0.05) compared with those in saline controls.	Metronidazole	16-29	interleukin 1 beta	Mus musculus	107-116
9040200-12	1997	In patients with metronidazole-sensitive (M-S) strains versus M-R strains, the cure rates were 96 versus 77% with OAM (p = 0.025), 94 versus 94% with OCM, and 94 versus 96% with BCM.	Metronidazole	17-30	TNF receptor superfamily member 17	Homo sapiens	178-181
9178689-7	1997	Oral administration of antibiotics (kanamycin and/or metronidazole for 2 days) significantly reduced constitutive ICAM-1 expression in the cecum, but not in the distal colon.	Metronidazole	53-66	intercellular adhesion molecule 1	Rattus norvegicus	114-120
8244360-6	1993	RESULTS: Survival analysis showed a significantly faster disappearance of symptoms in the metronidazole category compared with both lactic acid and placebo (p = 0.0005 metronidazole v placebo, p = 0.0002 metronidazole v lactic acid p = 0.6521 lactic acid v placebo [The stratified Mantel Cox test]).	Metronidazole	90-103	cytochrome c oxidase subunit 8A	Homo sapiens	288-291
8971305-17	1996	CONCLUSIONS: In the elderly, triple therapy with omeprazole+metronidazole+clarithromycin for 1 week is well tolerated and highly effective; anti-H. pylori antibody and PGC serum levels decrease soon after anti-H. pylori therapy only in patients cured of H. pylori infection.	Metronidazole	60-73	progastricsin	Homo sapiens	168-171
7797043-7	1995	Combined treatment of the normally colonized rats with neomycin, polymyxin B, and metronidazole for 7 days largely protected the animal from PAF-induced shock and intestinal necrosis.	Metronidazole	82-95	PCNA clamp associated factor	Rattus norvegicus	141-144
7945401-5	1994	All except guanine resulted in interaction with the metronidazole nitro radical anion (RNO2-), as measured by the decrease in the return-to-forward peak current ratio, in the following order of increasing reactivity: cytosine, adenine and thymine (at a metronidazole: base ratio of 1:1).	Metronidazole	52-65	NLR family pyrin domain containing 12	Homo sapiens	87-91
7513805-0	1994	Metronidazole hprt mutation induction in sheep and the relationship with its elimination rate.	Metronidazole	0-13	hypoxanthine-guanine phosphoribosyltransferase	Ovis aries	14-18
7513805-1	1994	Gene mutations at the hprt locus were determined in peripheral blood lymphocytes from nine sheep treated with metronidazole (MZ) at therapeutic doses for amebiasis.	Metronidazole	110-123	hypoxanthine-guanine phosphoribosyltransferase	Ovis aries	22-26
7513805-1	1994	Gene mutations at the hprt locus were determined in peripheral blood lymphocytes from nine sheep treated with metronidazole (MZ) at therapeutic doses for amebiasis.	Metronidazole	125-127	hypoxanthine-guanine phosphoribosyltransferase	Ovis aries	22-26
8884643-9	1996	While the GCF TIMP level did not change significantly in the scaling and root planing alone group, it significantly increased for all three adjunctive antimicrobial treatments (for tetracycline fiber P < 0.001, minocycline gel P = 0.005, metronidazole gel P < 0.001).	Metronidazole	241-254	TIMP metallopeptidase inhibitor 1	Homo sapiens	14-18
7626074-0	1995	Inhibition of diamine oxidase activity by metronidazole.	Metronidazole	42-55	amine oxidase copper containing 1	Homo sapiens	14-29
7626074-2	1995	These findings suggest that metronidazole and similar compounds, used as antibacterial and antiprotozoal drugs, should be given under careful control, especially when administered for long times, because a decrease of intestinal diamine oxidase activity was proven to be a risk factor for several pathologies of this organ.	Metronidazole	28-41	amine oxidase copper containing 1	Homo sapiens	229-244
7650197-2	1995	A selective medium containing mupirocin and metronidazole was evaluated for the isolation of Actinomyces spp.	Metronidazole	44-57	histocompatibility minor 13	Homo sapiens	105-108
1513881-3	1992	Deletion analysis indicated that ORF1 conferred the metronidazole resistance phenotype and encoded a protein with an apparent M(r) of approximately 8-10 kDa.	Metronidazole	52-65	hypothetical protein	Escherichia coli	33-37
1639504-9	1992	Detachment was observed for all strains tested and was also dependent on the viability of T. denticola: UV light, heat, and metronidazole treatment markedly reduced the HGF detachment response.	Metronidazole	124-137	hepatocyte growth factor	Homo sapiens	169-172
1320691-1	1992	In the present study in vitro interactions of disulfiram (an agent used to induce ethanol intolerance in alcoholics), diethyldithiocarbamate (DDC), and metronidazole with central benzodiazepine receptors (CBR) and peripheral benzodiazepine (BZ) receptors (PBR) were investigated in rat tissues.	Metronidazole	152-165	translocator protein	Rattus norvegicus	256-259
7805573-4	1993	This will result in passive, Donnan-mediated K+, Cl- and HCO3- fluxes into astrocytes, which in turn causes swelling and a collapse of the ECS.	Metronidazole	29-35	epistatic circling SWR/J	Mus musculus	139-142
8492751-9	1993	The overall rate of success with modifications (Amphotericin B, Vancomycin, Clindamycin, Metronidazole) was higher in Reg.	Metronidazole	89-102	regenerating family member 1 alpha	Homo sapiens	118-121
1473785-2	1992	The cytochrome P-450-inducing capacity of isolated intact broccoli glucosinolates and their degradation products, resulting from myrosinase-catalysed hydrolysis, has been assessed in studies of the metabolism of antipyrine (AP) and metronidazole (MZ) in the rat.	Metronidazole	247-249	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	4-20
1544834-3	1992	All target molecules, except adenosine and guanine, resulted in interaction with RNO2.-, as measured by the decrease in the ipr/ipf ratio in the following order of increasing reactivity: adenine, guanosine, thymine, uracil, uridine, and thymidine (at a metronidazole:target ratio of 1:1).	Metronidazole	253-266	NLR family pyrin domain containing 12	Homo sapiens	81-85
1916494-4	1991	Changes in C reactive protein concentrations did not achieve significance when all three groups were considered but were significant when all metronidazole treated patients were grouped and compared with the placebo treated patients (0.8 v -0.9, p less than 0.05).	Metronidazole	142-155	C-reactive protein	Homo sapiens	11-29
1410803-6	1992	Study of the temperature-dependent parameters of the enzymes showed that metronidazole induced a shift in the transition temperature (To) in LAP with nearly total reversibility in the recovery group.	Metronidazole	73-86	leucine aminopeptidase 3	Rattus norvegicus	141-144
2375881-2	1990	2 The plasma clearance of metronidazole was 1.20 +/- 0.53 and 1.25 +/- 0.22 ml min-1 kg-1, the volume of distribution 0.77 +/- 0.27 and 0.77 +/- 0.09 1 kg-1 and the half-life 7.8 +/- 1.9 and 7.2 +/- 0.9 h in elderly and young subjects, respectively (P less than 0.05).	Metronidazole	26-39	CD59 molecule (CD59 blood group)	Homo sapiens	79-89
2019363-5	1991	Antimicrobial therapy (bismuth, tetracycline, and metronidazole) to eradicate the H. pylori infection was associated with a significant reduction in bombesin-stimulated gastrin release in patients with duodenal ulcer (from 116.9 +/- 19 pg/mL to 69.5 +/- 7 pg/mL following 50 pmol.kg-1.h-1 bombesin; and from 158 +/- 29 to 83.4 +/- 10 following 200 pmol.kg-1.h-1 bombesin: P = 0.01 for each).	Metronidazole	50-63	gastrin releasing peptide	Homo sapiens	149-157
2019363-5	1991	Antimicrobial therapy (bismuth, tetracycline, and metronidazole) to eradicate the H. pylori infection was associated with a significant reduction in bombesin-stimulated gastrin release in patients with duodenal ulcer (from 116.9 +/- 19 pg/mL to 69.5 +/- 7 pg/mL following 50 pmol.kg-1.h-1 bombesin; and from 158 +/- 29 to 83.4 +/- 10 following 200 pmol.kg-1.h-1 bombesin: P = 0.01 for each).	Metronidazole	50-63	gastrin	Homo sapiens	169-176
2019363-5	1991	Antimicrobial therapy (bismuth, tetracycline, and metronidazole) to eradicate the H. pylori infection was associated with a significant reduction in bombesin-stimulated gastrin release in patients with duodenal ulcer (from 116.9 +/- 19 pg/mL to 69.5 +/- 7 pg/mL following 50 pmol.kg-1.h-1 bombesin; and from 158 +/- 29 to 83.4 +/- 10 following 200 pmol.kg-1.h-1 bombesin: P = 0.01 for each).	Metronidazole	50-63	gastrin releasing peptide	Homo sapiens	289-297
2019363-5	1991	Antimicrobial therapy (bismuth, tetracycline, and metronidazole) to eradicate the H. pylori infection was associated with a significant reduction in bombesin-stimulated gastrin release in patients with duodenal ulcer (from 116.9 +/- 19 pg/mL to 69.5 +/- 7 pg/mL following 50 pmol.kg-1.h-1 bombesin; and from 158 +/- 29 to 83.4 +/- 10 following 200 pmol.kg-1.h-1 bombesin: P = 0.01 for each).	Metronidazole	50-63	gastrin releasing peptide	Homo sapiens	289-297
34085303-9	2021	The resulting 15 N polarization (maximal value about 4% achieved for metronidazole and pyridine at 45 o C degree) strongly depends on the sample temperature, pH2 bubbling pressure and pH2 flow.	Metronidazole	69-82	polyhomeotic homolog 2	Homo sapiens	158-161
2143301-1	1990	Metronidazole cream 1% was applied externally for the treatment of rosacea during 2 months in 14 women and 6 men.	Metronidazole	0-13	GTF2I repeat domain containing 1	Homo sapiens	14-21
34341928-6	2022	Furthermore, MNZ significantly increased the number of preneoplastic liver foci, accompanied by DNA double-strand breaks and late-stage autophagy inhibition, as reflected by increased levels of gamma-H2AX, LC3, and p62.	Metronidazole	13-16	annexin A3	Rattus norvegicus	206-209
34341928-6	2022	Furthermore, MNZ significantly increased the number of preneoplastic liver foci, accompanied by DNA double-strand breaks and late-stage autophagy inhibition, as reflected by increased levels of gamma-H2AX, LC3, and p62.	Metronidazole	13-16	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	215-218
33798117-0	2021	Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt.	Metronidazole	60-73	propionyl-CoA carboxylase subunit alpha	Homo sapiens	89-93
33798117-8	2021	The purpose of this study was to determine the physicochemical and microbiological stability of extemporaneously compounded metronidazole suspensions in PCCA SuspendIt.	Metronidazole	124-137	propionyl-CoA carboxylase subunit alpha	Homo sapiens	153-157
33798117-11	2021	A robust stability-indicating ultra-performance liquid chromatographic assay for the determination of the chemical stability of metronidazole in PCCA SuspendIt was developed and validated.	Metronidazole	128-141	propionyl-CoA carboxylase subunit alpha	Homo sapiens	145-149
33798117-22	2021	This study demonstrates that metronidazole is physically, chemically, and microbiologically stable in PCCA SuspendIt for 180 days in the refrigerator and at room temperature, thus providing a viable, compounded alternative for metronidazole in a liquid dosage form, with an extended beyond-use-date to meet patient needs.	Metronidazole	29-42	propionyl-CoA carboxylase subunit alpha	Homo sapiens	102-106
34085303-9	2021	The resulting 15 N polarization (maximal value about 4% achieved for metronidazole and pyridine at 45 o C degree) strongly depends on the sample temperature, pH2 bubbling pressure and pH2 flow.	Metronidazole	69-82	polyhomeotic homolog 2	Homo sapiens	184-187
34491014-1	2021	OBJECTIVE: To investigate various factors affecting the clinical outcome of nonsurgical periodontal treatment and evaluate the treatment effects of adjunctive amoxicillin and metronidazole (AMX + MET) in patients with generalised aggressive periodontitis (GAgP).	Metronidazole	175-188	SAFB like transcription modulator	Homo sapiens	196-199
34827338-0	2021	Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics.	Metronidazole	11-24	insulin	Homo sapiens	78-85
34454095-0	2021	Targeting antibiotic tolerance in anaerobic biofilms associated with oral diseases: Human antimicrobial peptides LL-37 and lactoferricin enhance the antibiotic efficacy of amoxicillin, clindamycin and metronidazole.	Metronidazole	201-214	cathelicidin antimicrobial peptide	Homo sapiens	113-118
34454095-0	2021	Targeting antibiotic tolerance in anaerobic biofilms associated with oral diseases: Human antimicrobial peptides LL-37 and lactoferricin enhance the antibiotic efficacy of amoxicillin, clindamycin and metronidazole.	Metronidazole	201-214	lactotransferrin	Homo sapiens	123-136
34162101-1	2021	In this study, granular activated carbon (GAC) was examined for the removal of five of the most commonly detected pharmaceuticals (naproxen, carbamazepine, acetaminophen, ibuprofen and metronidazole) from a nitrified urine to make the urine-derived fertiliser nutrient safe for food crops.	Metronidazole	185-198	glutaminase	Homo sapiens	42-45
34572583-4	2021	Based on the Nitroreductase/Metronidazole (NTR/MTZ) cell ablation system, we constructed a Tg(cdh17:Dendra2-NTR) transgenic zebrafish line, which can specifically ablate renal tubular epithelial cells.	Metronidazole	28-41	cadherin 17, LI cadherin (liver-intestine)	Danio rerio	94-99
34827338-1	2021	Treating periodontitis with metronidazole (MET) as an adjunct to scaling root planing (SRP) is suggested to have inconsistent effects on insulin resistance (IR) in type 2 diabetes mellitus (T2DM).	Metronidazole	28-41	SAFB like transcription modulator	Homo sapiens	43-46
34752478-10	2021	Administration of metronidazole itself influenced significantly mRNA expression of Cyp1a2, Cyp2b10, Cyp2c38 and Cyp2d22.	Metronidazole	18-31	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	83-89
34752478-10	2021	Administration of metronidazole itself influenced significantly mRNA expression of Cyp1a2, Cyp2b10, Cyp2c38 and Cyp2d22.	Metronidazole	18-31	cytochrome P450, family 2, subfamily d, polypeptide 22	Mus musculus	112-119
34637255-3	2021	In this work, personalized and defect-specific antibiotic-laden polymeric scaffolds containing metronidazole (MET), tetracycline (TCH), or their combination (MET/TCH) were created via electrospinning.	Metronidazole	95-108	SAFB like transcription modulator	Homo sapiens	110-113
34639039-8	2021	Suppression of the protozoan infection with efficient metronidazole dosage or L-fucose administration resulted in amelioration of an illness observed in antibiotic-treated Muc2-/- mice.	Metronidazole	54-67	mucin 2	Mus musculus	172-176
35623028-4	2022	MTZ at different concentrations (1, 2, 5, and 10 mg mL-1) was loaded into chitosan-sodium tripolyphosphate NPs.	Metronidazole	0-3	L1 cell adhesion molecule	Mus musculus	52-56
34464376-12	2021	She was successfully treated for Clostridioides difficile with metronidazole and probiotics, and had complete clinical remission of the Wells syndrome with mometasone furoate cream and levocetirizine.	Metronidazole	63-76	Src homology 2 domain containing E	Homo sapiens	0-3
34148466-8	2021	In mild-to-moderate Crohn"s disease, azithromycin+metronidazole (AZ+MET) (n=35) compared to metronidazole (MET) alone (n=38) did not induce a significantly different response (PCDAI drop >=12.5 points or remission) (p=0.07).	Metronidazole	50-63	SAFB like transcription modulator	Homo sapiens	65-71
35533848-2	2022	In this research, we demonstrated the use of natural rubber latex (NRL) from Hevea brasiliensis as a carrier of AuNPs and the antibiotic metronidazole (MET).	Metronidazole	137-150	SAFB like transcription modulator	Homo sapiens	152-155
34285790-1	2021	Aims: An antibiotic combination of amoxicillin, tetracycline and metronidazole (ATM) is effective for ulcerative colitis (UC), but this regimen is discontinued in some cases due to adverse events.	Metronidazole	65-78	ATM serine/threonine kinase	Homo sapiens	80-83
35088259-10	2022	Amplification of the metronidazole rdx gene was performed by conventional PCR.	Metronidazole	21-34	radixin	Homo sapiens	35-38
35483564-4	2022	Here, we report the construction of a T-cell ablation model in Tg(coro1a:DenNTR) zebrafish via metronidazole administration.	Metronidazole	95-108	coronin, actin binding protein, 1A	Danio rerio	66-72
35487253-6	2022	As well, OCT combined with MTZ/CLR restored the integrity of gastric mucosa damaged by H. pylori via elevating the expression of Muc5ac and somatostatin receptor 2, decreasing inflammation and increasing the number of chorionic or glands.	Metronidazole	27-30	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	129-135
35487253-6	2022	As well, OCT combined with MTZ/CLR restored the integrity of gastric mucosa damaged by H. pylori via elevating the expression of Muc5ac and somatostatin receptor 2, decreasing inflammation and increasing the number of chorionic or glands.	Metronidazole	27-30	somatostatin receptor 2	Homo sapiens	140-163
35066223-3	2022	Thus, by applying HCP-Kae1-24 h as a solid-phase extraction adsorbent, a sensitive method was developed for enrichment of 5-NDZs including metronidazole, ronidazole, secnidazole, dimetridazole and ornidazole prior to high performance liquid chromatography analysis.	Metronidazole	139-152	O-sialoglycoprotein endopeptidase	Homo sapiens	22-26
35456697-6	2022	The rate of metronidazole release from the floating tablets (K = 6.278 mg min-1/2) was significantly lower than that from conventional tablets (K = 10.666 mg min-1/2), indicating sustained drug release, according to the Higuchi model, for more than 6 h in an acidic medium of 0.1 N HCl.	Metronidazole	12-25	CD59 molecule (CD59 blood group)	Homo sapiens	74-81
35412828-5	2022	Particularly, 1-hydroxybenzoisochromanquinone (17) and benzo(g)isoquinoline-5,10-dione (18), with MIC values of 0.0625 and 0.125 mug/mL, displayed 32-512-fold higher potencies than a positive control, metronidazole.	Metronidazole	201-214	thrombopoietin	Mus musculus	133-135
35440306-1	2022	BACKGROUND: A combination of antibiotics, including metronidazole (MET), ciprofloxacin (CIP), and minocycline (MINO), has been demonstrated to disinfect bacteria in necrotic teeth before regenerative processes.	Metronidazole	52-65	SAFB like transcription modulator	Homo sapiens	67-70
35456697-6	2022	The rate of metronidazole release from the floating tablets (K = 6.278 mg min-1/2) was significantly lower than that from conventional tablets (K = 10.666 mg min-1/2), indicating sustained drug release, according to the Higuchi model, for more than 6 h in an acidic medium of 0.1 N HCl.	Metronidazole	12-25	CD59 molecule (CD59 blood group)	Homo sapiens	158-165
35140461-3	2022	In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-CHL) or metronidazole (AgNPs-PEG-MET) to determine whether they can be used to treat PDs.	Metronidazole	133-146	SAFB like transcription modulator	Homo sapiens	158-161
35368951-3	2022	In order to inhibit the proliferation of bacteria in the dental pulp, metronidazole (MTR) is loaded into MSN.	Metronidazole	70-83	moesin	Homo sapiens	105-108
35368951-3	2022	In order to inhibit the proliferation of bacteria in the dental pulp, metronidazole (MTR) is loaded into MSN.	Metronidazole	85-88	moesin	Homo sapiens	105-108
35329594-4	2022	Composite printlets consisting of sintered carbon-stained polyamide (PA12) and metronidazole (Met) were manufactured by SLS to overcome the issue.	Metronidazole	79-92	SAFB like transcription modulator	Homo sapiens	94-97
35160444-4	2022	This study anticipated to develop a new composite metronidazole (MTZ) immobilized nanofibrous scaffold based on poly (3-hydroxy butyrate) (PHB) and Gelatin (Gel) to be utilized as a novel secondary intention wound healing accelerator.	Metronidazole	50-63	prohibitin 1	Homo sapiens	139-142
35132245-3	2022	Here we used rational engineering and cross-species screening to develop an NTR variant, NTR 2.0, which exhibits ~100-fold improvement in MTZ-mediated cell-specific ablation efficacy, eliminating the need for near-toxic prodrug treatment regimens.	Metronidazole	138-141	neurotensin receptor 2	Homo sapiens	89-94
35160444-4	2022	This study anticipated to develop a new composite metronidazole (MTZ) immobilized nanofibrous scaffold based on poly (3-hydroxy butyrate) (PHB) and Gelatin (Gel) to be utilized as a novel secondary intention wound healing accelerator.	Metronidazole	65-68	prohibitin 1	Homo sapiens	139-142
35160444-7	2022	The properties of MTZ immobilized PHB/Gel nanofibrous scaffold were evaluated (SEM, FTIR, TGA, water uptake, contact angle, porosity, mechanical properties and antibacterial activity).	Metronidazole	18-21	prohibitin 1	Homo sapiens	34-37
35160444-10	2022	These results indicate that MTZ immobilized PHB/Gel nanofibrous scaffold significantly boost accelerating secondary intention wound healing.	Metronidazole	28-31	prohibitin 1	Homo sapiens	44-47
2816220-2	1989	The mean elimination half-life of metronidazole was 8 h and the mean apparent volume of distribution 42 l. At 1-4 h after the infusion the median tissue/serum drug concentration ratio was 0.94 for rectus abdominis muscle and 0.76 for colonic mucosa.	Metronidazole	34-47	angiotensin II receptor type 1	Homo sapiens	107-113
35055155-2	2022	Clindamycin (CLIN) or metronidazole (MET) was added to a polymer solution and electrospun into fibrous mats, which were processed via cryomilling to obtain CLIN- or MET-laden fibrous microparticles.	Metronidazole	22-35	SAFB like transcription modulator	Homo sapiens	37-40
35055155-2	2022	Clindamycin (CLIN) or metronidazole (MET) was added to a polymer solution and electrospun into fibrous mats, which were processed via cryomilling to obtain CLIN- or MET-laden fibrous microparticles.	Metronidazole	22-35	SAFB like transcription modulator	Homo sapiens	165-168
2485892-14	1989	Metronidazole was active against high percentage of Clostridium spp.	Metronidazole	0-13	histocompatibility minor 13	Homo sapiens	64-67
2722021-3	1989	Electrochemical studies on metronidazole using mixed aqueous/dimethylformamide (DMF) solvents have allowed us to generate the one-electron addition product, the nitro radical anion, RNO2(-.).	Metronidazole	27-40	NLR family pyrin domain containing 12	Homo sapiens	182-186
2968903-1	1988	In 55 inoperable patients with lung cancer the use of tinidizole and metronidazole with X-ray therapy intensified the immunoregulative disbalance, increased the quantity of circulative immune complexes and reduced the Na+K+-ATPase activity of erythrocyte membranes in contrast to the data obtained from patients receiving only X-ray therapy.	Metronidazole	69-82	dynein axonemal heavy chain 8	Homo sapiens	224-230
2897213-2	1988	Metronidazole was first administered alone (250 mg bid, po) and then with prednisone (10 mg bid, po), sulfasalazine (1 g bid, po), cimetidine (600 mg bid) or phenobarbital (60 mg bid, po).	Metronidazole	0-13	BH3 interacting domain death agonist	Homo sapiens	51-54
2897213-2	1988	Metronidazole was first administered alone (250 mg bid, po) and then with prednisone (10 mg bid, po), sulfasalazine (1 g bid, po), cimetidine (600 mg bid) or phenobarbital (60 mg bid, po).	Metronidazole	0-13	BH3 interacting domain death agonist	Homo sapiens	92-95
2897213-2	1988	Metronidazole was first administered alone (250 mg bid, po) and then with prednisone (10 mg bid, po), sulfasalazine (1 g bid, po), cimetidine (600 mg bid) or phenobarbital (60 mg bid, po).	Metronidazole	0-13	BH3 interacting domain death agonist	Homo sapiens	92-95
2897213-2	1988	Metronidazole was first administered alone (250 mg bid, po) and then with prednisone (10 mg bid, po), sulfasalazine (1 g bid, po), cimetidine (600 mg bid) or phenobarbital (60 mg bid, po).	Metronidazole	0-13	BH3 interacting domain death agonist	Homo sapiens	92-95
2897213-2	1988	Metronidazole was first administered alone (250 mg bid, po) and then with prednisone (10 mg bid, po), sulfasalazine (1 g bid, po), cimetidine (600 mg bid) or phenobarbital (60 mg bid, po).	Metronidazole	0-13	BH3 interacting domain death agonist	Homo sapiens	92-95
3039569-1	1987	A study was made of changes in the intensity of the ESR signals in tissues of sarcoma-37 and liver of mice after radiation of the tumor, administration of metronidazole, and after the combined effect of the two factors.	Metronidazole	155-168	esterase 5 regulator	Mus musculus	52-55
3039569-2	1987	The most pronounced changes in the ESR signals were induced by metronidazole.	Metronidazole	63-76	esterase 5 regulator	Mus musculus	35-38
3000170-12	1985	In the past 1 1/2 years we have encountered three unusual cases involving individuals who were treated with large doses of metronidazole for Crohn"s disease and who developed a malignant neoplasm at a relatively young age.	Metronidazole	123-136	EH domain containing 2	Homo sapiens	7-17
2942503-1	1986	A first attempt to impair a biological function by the synergistic effects of HpD and nitroimidazoles (metronidazole or misonidazole) under anaerobic conditions is reported.	Metronidazole	103-116	4-hydroxyphenylpyruvate dioxygenase	Homo sapiens	78-81
2942503-6	1986	Thus, under these experimental conditions, the enhancement ratio of the HpD action (defined as the ratio of the durations of irradiation necessary to obtain the cessation of Ca2+ uptake before and after addition of a component other than HpD) is of the order of 40, 10 and 5 for oxygen, misonidazole and metronidazole, respectively.	Metronidazole	304-317	4-hydroxyphenylpyruvate dioxygenase	Homo sapiens	72-75
2436472-1	1987	Herein we report a 56-yr-old man with amebic liver abscess associated with a high level of alpha-fetoprotein that subsequently reduced to an undetectable level after successful treatment with metronidazole.	Metronidazole	192-205	alpha fetoprotein	Homo sapiens	91-108
3842381-1	1985	Effect of metronidazole (MNZ) treatment (oral and ip) on activities of cytochrome b5 and P-450 was studied in male, virgin and pregnant female mice.	Metronidazole	10-23	cytochrome b5 type A (microsomal)	Mus musculus	71-84
3842381-1	1985	Effect of metronidazole (MNZ) treatment (oral and ip) on activities of cytochrome b5 and P-450 was studied in male, virgin and pregnant female mice.	Metronidazole	25-28	cytochrome b5 type A (microsomal)	Mus musculus	71-84
6513753-1	1984	The use of metronidazole in radiation therapy of laryngeal cancer (SFD = 20 Gy) as a radiosensitizer of tumor hypoxic cells resulted in changes of the liver function tests: a decrease in the cholinesterase activity, a decrease in the level of cholesterol and albumin esters in the blood serum that characterize synthetic liver function.	Metronidazole	11-24	butyrylcholinesterase	Homo sapiens	191-205
2863398-7	1985	The administration of metronidazole during TPN was associated with prevention of the expected rise of serum alkaline phosphatase, gamma glutamyl transpeptidase, and aspartate amino-transferase.	Metronidazole	22-35	inactive glutathione hydrolase 2	Homo sapiens	130-159
6332091-0	1984	Association of the radiosensitizers metronidazole and misonidazole (RO-07-0582) with bovine serum albumin.	Metronidazole	36-49	albumin	Homo sapiens	92-105
6491976-7	1984	Metronidazole treatment increased the elimination rate constant for endogenous prothrombin complex activity and decreased the plasma concentration of free R-(+)-warfarin required to decrease prothrombin complex activity synthesis rate to one-half of normal (there were insufficient data to determine the effect of metronidazole on the activity of the other enantiomer).	Metronidazole	0-13	coagulation factor II	Rattus norvegicus	79-90
6491976-7	1984	Metronidazole treatment increased the elimination rate constant for endogenous prothrombin complex activity and decreased the plasma concentration of free R-(+)-warfarin required to decrease prothrombin complex activity synthesis rate to one-half of normal (there were insufficient data to determine the effect of metronidazole on the activity of the other enantiomer).	Metronidazole	0-13	coagulation factor II	Rattus norvegicus	191-202
6467795-8	1984	min-1; 25% of metronidazole in the body at the beginning of hemodialysis was eliminated.	Metronidazole	14-27	CD59 molecule (CD59 blood group)	Homo sapiens	0-5
6332091-2	1984	The stability of association of nitroimidazole radiosensitizers (metronidazole and misonidazole) with bovine serum albumin (BSA) was examined in aqueous solutions by 1H n.m.r.	Metronidazole	65-78	albumin	Homo sapiens	109-122
7170650-0	1982	Cholinesterase activity after treatment with mebendazole, thiabendazole and metronidazole in patients with various parasitic diseases.	Metronidazole	76-89	butyrylcholinesterase	Homo sapiens	0-14
6714438-4	1984	By using cells from patients deficient in glutathione synthetase, we found that cells with decreased glutathione defenses are more sensitive to toxicity from metabolites of drugs such as acetaminophen, nitrofurantoin, and metronidazole.	Metronidazole	222-235	glutathione synthetase	Homo sapiens	42-64
6617070-2	1983	After 400 mg metronidazole IV, mean Vd beta was 1.05 l/kg.	Metronidazole	13-26	GC vitamin D binding protein	Homo sapiens	36-43
6612225-0	1983	Effects of metronidazole (Flagyl) on the determination of serum ASAT on the SMA 12/60 Auto Analyser.	Metronidazole	11-24	ATP binding cassette subfamily B member 7	Homo sapiens	64-68
6612225-0	1983	Effects of metronidazole (Flagyl) on the determination of serum ASAT on the SMA 12/60 Auto Analyser.	Metronidazole	11-24	survival of motor neuron 1, telomeric	Homo sapiens	76-79
6612225-0	1983	Effects of metronidazole (Flagyl) on the determination of serum ASAT on the SMA 12/60 Auto Analyser.	Metronidazole	26-32	ATP binding cassette subfamily B member 7	Homo sapiens	64-68
6612225-0	1983	Effects of metronidazole (Flagyl) on the determination of serum ASAT on the SMA 12/60 Auto Analyser.	Metronidazole	26-32	survival of motor neuron 1, telomeric	Homo sapiens	76-79
6612225-1	1983	Therapeutic serum concentrations of metronidazole will lead to under-estimation of ASAT activity when a SMA 12/60 Auto Analyser is used.	Metronidazole	36-49	ATP binding cassette subfamily B member 7	Homo sapiens	83-87
6612225-1	1983	Therapeutic serum concentrations of metronidazole will lead to under-estimation of ASAT activity when a SMA 12/60 Auto Analyser is used.	Metronidazole	36-49	survival of motor neuron 1, telomeric	Homo sapiens	104-107
6612225-2	1983	This interference is due to metronidazole entering the colorimeter through the dialyser membrane in the SMA 12/60 Auto Analyser.	Metronidazole	28-41	survival of motor neuron 1, telomeric	Homo sapiens	104-107
6612225-4	1983	Metronidazole will similarily affect other 340 nm methods (LDH, ALAT) available on the SMA 12/60.	Metronidazole	0-13	survival of motor neuron 1, telomeric	Homo sapiens	87-90
6612225-5	1983	This interference with metronidazole on the SMA 12/60 can easily be solved by the introduction of a separate serum blank channel for the 340 nm methods.	Metronidazole	23-36	survival of motor neuron 1, telomeric	Homo sapiens	44-47
7107382-1	1982	We have studied the effect of misonidazole (MISO) or metronidazole (MET) pretreatment upon the response of the RIF-1 mouse tumor to cytotoxic drugs.	Metronidazole	53-66	replication timing regulatory factor 1	Mus musculus	111-116
7073938-0	1982	Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.	Metronidazole	26-39	replication timing regulatory factor 1	Mus musculus	76-81
7313587-5	1981	A 1-week course of metronidazole (200 mg 3 times daily) was successful in 8/9 failures; 1 patient was finally cured with mepacrine.	Metronidazole	19-32	BCL2 related protein A1	Homo sapiens	0-3
7421713-0	1980	Interference of metronidazole (Flagyl) with serum aspartate aminotransferase (AST) assays.	Metronidazole	16-29	solute carrier family 17 member 5	Homo sapiens	50-76
7421713-0	1980	Interference of metronidazole (Flagyl) with serum aspartate aminotransferase (AST) assays.	Metronidazole	16-29	solute carrier family 17 member 5	Homo sapiens	78-81
7457495-5	1980	Serum levels of metronidazole several times in excess of the minimal inhibitory concentrations for the organisms were easily achieved and in one patient the CSF metronidazole level was equal to that of the serum.	Metronidazole	161-174	colony stimulating factor 2	Homo sapiens	157-160
7421713-0	1980	Interference of metronidazole (Flagyl) with serum aspartate aminotransferase (AST) assays.	Metronidazole	31-37	solute carrier family 17 member 5	Homo sapiens	50-76
225190-1	1979	In the homogenate of the liver biochemically examined 45 hrs after a single 250 mg dose of metronidazole administration, a 45% increase of c-AMP level was found as compared with controls.	Metronidazole	91-104	cathelicidin antimicrobial peptide	Rattus norvegicus	139-144
7446875-1	1980	A rapid and sensitive analytic method for metronidazole (Flagyl) using high performance liquid chromatography is described; the use of a column filled with grafted silicium, lichrosorb RP 8, permits the direct injection of a plasma treated with perchloric acid and then centrifuged.	Metronidazole	57-63	programmed cell death 2	Homo sapiens	185-189
675837-4	1978	The rate of build-up of microfilariae over a follow-up period of 24 months after treatment with the drug under test followed by DEC (a measure of macrofilaricidal action) was slowest in the groups treated with metronidazole and trichlorophone (22.9% and 27.0% of the pre-treatment counts respectively).	Metronidazole	210-223	phosphatase and tensin homolog	Homo sapiens	128-131
646342-1	1978	A rapid and sensitive high-pressure liquid chromatography assay for metronidazole and its two principle metabolites, 1-(2-hydroxyethyl-2-hydroxymethyl)-5-nitro-imidazole [hydroxy metabolite] and 1-acetic acid-2-methyl-5-metronidazole [acid metabolite], was developed.	Metronidazole	68-81	PTOV1 extended AT-hook containing adaptor protein	Homo sapiens	204-210
32761620-0	2021	Diagnostic work-up including CD203c-based basophil activation test in immediate hypersensitivity due to metronidazole and ornidazole and evaluation of cross-reactivity in between.	Metronidazole	104-117	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	29-35
4320226-0	1970	Effect of metronidazole on liver alcohol dehydrogenase.	Metronidazole	10-23	aldo-keto reductase family 1 member A1	Homo sapiens	33-54
33975173-3	2021	The method produced linear responses in the concentration range 4.28 - 59.91 microg mL-1 with limit of detection (LOD) and limit of quantification (LOQ) 0.21 and 0.69 microg mL-1 for Metronidazole drug respectively.	Metronidazole	183-196	L1 cell adhesion molecule	Mus musculus	84-88
33975173-3	2021	The method produced linear responses in the concentration range 4.28 - 59.91 microg mL-1 with limit of detection (LOD) and limit of quantification (LOQ) 0.21 and 0.69 microg mL-1 for Metronidazole drug respectively.	Metronidazole	183-196	L1 cell adhesion molecule	Mus musculus	174-178
33341580-4	2021	Dy(VO4)/f-CNF/SPCE delivers a higher active surface area recommends superior electrocatalytic activity which is favorable for the MEZ sensor.	Metronidazole	130-133	NPHS1 adhesion molecule, nephrin	Homo sapiens	10-13
33341580-8	2021	Thus, Dy(VO4)/f-CNF nanocomposite modified SPCE considers being a potential candidate for the MEZ sensor.	Metronidazole	94-97	NPHS1 adhesion molecule, nephrin	Homo sapiens	16-19
33753483-4	2021	Transient depletion of IL-10-producing cells from adult ICOSL-deficient mice induced severe colonic inflammation that was prevented when mice were first treated with metronidazole.	Metronidazole	166-179	interleukin 10	Mus musculus	23-28
33753483-4	2021	Transient depletion of IL-10-producing cells from adult ICOSL-deficient mice induced severe colonic inflammation that was prevented when mice were first treated with metronidazole.	Metronidazole	166-179	icos ligand	Mus musculus	56-61
33743421-3	2021	Subsequently, photocatalytic removal of metronidazole (MET) was investigated using ACN.	Metronidazole	40-53	SAFB like transcription modulator	Homo sapiens	55-58
265526-6	1977	Ferredoxin is necessary for metronidazole reduction by thylakoid membrane fractions enriched in photosystem l activity.	Metronidazole	28-41	uncharacterized protein	Chlamydomonas reinhardtii	0-10
265526-8	1977	The results indicate that mutants of C. reinhardtii, and probably other photosynthetic organisms, with any lesion in photosynthetic electron transport from the oxidizing side of photosystem ll to ferredoxin can be isolated by metronidazole treatment of mutagenized cultures.	Metronidazole	226-239	uncharacterized protein	Chlamydomonas reinhardtii	196-206
1071540-12	1976	Three cases in Group 1 showing lowered lactase levels were given metronidazole and showed remission of clinical symptoms, raising the possibility that they had undiagnosed infections with Giardia lamblia.	Metronidazole	65-78	lactase	Homo sapiens	39-46
33926701-1	2021	It is crucial to determine and control the metronidazole (MET) ingredient in food and pharmaceuticals for human health and food safety.	Metronidazole	43-56	SAFB like transcription modulator	Homo sapiens	58-61
33751238-1	2021	OBJECTIVES: The aim is to explore the optimal drug dose and duration of adjunctive Amoxicillin-plus-Metronidazole (AMX/MET) to full-mouth scaling and planing (FMSRP) in periodontitis.	Metronidazole	100-113	SAFB like transcription modulator	Homo sapiens	115-122
32281016-4	2020	RESULTS: Metronidazole concentration correlated with lactoferrin (rho = 0.17, p = 0.015), CRP (rho = 0.23, p < 0.001) and number of diarrhoeal stools per day (rho = 0.29, p < 0.001).	Metronidazole	9-22	C-reactive protein	Homo sapiens	90-93
33246048-3	2021	In this work, the formation of a THEDES containing metronidazole (MET), the preferred first-line treatment for bacterial vaginosis (BV), was explored.	Metronidazole	51-64	SAFB like transcription modulator	Homo sapiens	66-69
32725680-0	2020	Dexamethasone combined metronidazole on mammary duct ectasia and its relationship with serum IL-10 and IL-17.	Metronidazole	23-36	interleukin 10	Homo sapiens	93-98
32725680-0	2020	Dexamethasone combined metronidazole on mammary duct ectasia and its relationship with serum IL-10 and IL-17.	Metronidazole	23-36	interleukin 17A	Homo sapiens	103-108
32725680-1	2020	AIM: To explore the effect of dexamethasone combined with metronidazole in the treatment of mammary duct ectasia (MDE) and its relationship with changes in serum interleukin-10 (IL-10) and IL-17 expression.	Metronidazole	58-71	interleukin 10	Homo sapiens	162-176
32725680-1	2020	AIM: To explore the effect of dexamethasone combined with metronidazole in the treatment of mammary duct ectasia (MDE) and its relationship with changes in serum interleukin-10 (IL-10) and IL-17 expression.	Metronidazole	58-71	interleukin 10	Homo sapiens	178-183
32725680-1	2020	AIM: To explore the effect of dexamethasone combined with metronidazole in the treatment of mammary duct ectasia (MDE) and its relationship with changes in serum interleukin-10 (IL-10) and IL-17 expression.	Metronidazole	58-71	interleukin 17A	Homo sapiens	189-194
33953879-7	2021	The Z. officinale extract"s minimum inhibitory concentration (MIC) in the 24-hr period was 25.00 mug mL-1, while it was 50.00 mug mL-1 for metronidazole.	Metronidazole	139-152	L1 cell adhesion molecule	Mus musculus	130-134
32992661-2	2020	The aim of this study was to analyze actual antibiotic resistance rates of H. pylori strains isolated from children with primary infections and to compare the incidence of mutations that determine resistance to clarithromycin (CH) and metronidazole (MET) in children with different clinical diagnoses.	Metronidazole	235-248	SAFB like transcription modulator	Homo sapiens	250-253
32151614-9	2020	Metronidazole also induces iNOS, eNOS, Bax and caspase 3 protein expressions whilst decreases the expression of Bcl2 in the brain tissue.	Metronidazole	0-13	nitric oxide synthase 2	Rattus norvegicus	27-31
32151614-9	2020	Metronidazole also induces iNOS, eNOS, Bax and caspase 3 protein expressions whilst decreases the expression of Bcl2 in the brain tissue.	Metronidazole	0-13	nitric oxide synthase 3	Rattus norvegicus	33-37
32151614-9	2020	Metronidazole also induces iNOS, eNOS, Bax and caspase 3 protein expressions whilst decreases the expression of Bcl2 in the brain tissue.	Metronidazole	0-13	BCL2 associated X, apoptosis regulator	Rattus norvegicus	39-42
32151614-9	2020	Metronidazole also induces iNOS, eNOS, Bax and caspase 3 protein expressions whilst decreases the expression of Bcl2 in the brain tissue.	Metronidazole	0-13	BCL2, apoptosis regulator	Rattus norvegicus	112-116
32246501-1	2020	BACKGROUND: Data on the impact of combination therapy (intravenous metronidazole [IV MTZ] plus oral vancomycin [PO VAN]) on clinical outcomes in intensive care untie (ICU ) patients with severe, non-fulminant CDI, including NAP1-positive samples, is lacking.	Metronidazole	67-80	nucleosome assembly protein 1 like 1	Homo sapiens	224-228
32461053-0	2021	Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.	Metronidazole	19-32	histocompatibility minor 13	Homo sapiens	95-98
32442163-3	2020	Metronidazole (15 mg/kg BID PO) was given to five horses with cecal cannulas.	Metronidazole	0-13	BH3 interacting domain death agonist	Equus caballus	24-27
31677380-6	2020	We found that intestinal inflammation and tissue damage were significantly reduced in mice treated with metronidazole when combined with anti-E. histolytica MIF antibodies, compared to metronidazole alone.	Metronidazole	104-117	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	157-160
32070560-4	2020	Intriguingly, the above strong violet emission could be highly selectively quenched by aromatic nitrophenols or antibiotic metronidazole (MET) in aqueous systems with fairly low detection limits.	Metronidazole	123-136	SAFB like transcription modulator	Homo sapiens	138-141
32188962-2	2020	The hybrid nature of this material is founded on two key elements: the presence of the DAT backbone induced the formation of hydrophobic regions that allowed efficient loading of a series of drugs of increasing hydrophobicity (Metronidazole, Benzocaine, Ibuprofen, Naproxen and Imipramine), while simultaneously endowing swelling-induced pH-responsiveness to the hydrogel.	Metronidazole	227-240	solute carrier family 6 member 3	Homo sapiens	87-90
32234669-12	2020	However, eight, including MMV676358 and MMV028694, which demonstrated potent sub-muM IC50s against assemblage A, B and metronidazole resistant parasites (0.3 muM and 0.9 muM respectively), may represent new leads for future drug development.	Metronidazole	119-132	latexin	Homo sapiens	81-84
31483922-0	2020	HLA-A*24:02 is associated with metronidazole-induced cutaneous adverse drug reactions in Han Chinese individuals: a pilot case-control study with both HLA gene and T cell receptor repertoire analysis.	Metronidazole	31-44	major histocompatibility complex, class I, A	Homo sapiens	0-5
32074497-2	2020	At present, proton-pump inhibitor and amoxicillin-based triple therapy, including clarithromycin (PAC) and metronidazole (PAM), are two commonly used first-line therapies for H. pylori infection, which has a high incidence and possibly poor prognosis worldwide.	Metronidazole	107-120	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	122-125
31483922-3	2020	The frequency of HLA-B*24:02 carriers among the McADR patients was 73.3%, which was significantly higher than that of the population controls (32.16%, OR=5.80, 95% CI=[1.80-18.72], Pc=0.004) and of the metronidazole-tolerant patients (26.67%, OR=7.56, 95% CI=[2.02-28.35], Pc=0.004).	Metronidazole	202-215	major histocompatibility complex, class I, B	Homo sapiens	17-22
31483922-4	2020	Molecular docking showed that metronidazole and one of its major metabolites had the potential to bind in the HLA groove and that there was a relatively stable binding state of the HLA-B*24:02-metronidazole/the metabolite complex.	Metronidazole	30-43	major histocompatibility complex, class I, B	Homo sapiens	181-186
31483922-4	2020	Molecular docking showed that metronidazole and one of its major metabolites had the potential to bind in the HLA groove and that there was a relatively stable binding state of the HLA-B*24:02-metronidazole/the metabolite complex.	Metronidazole	193-206	major histocompatibility complex, class I, B	Homo sapiens	181-186
31315136-5	2019	ALP reduction was greatest for vancomycin (65.6%, p < 0.002) and smallest with metronidazole (22.7%, p = 0.18).	Metronidazole	79-92	alkaline phosphatase, placental	Homo sapiens	0-3
33317789-4	2020	Medical available therapies as metronidazole, sucralfate, mesalizine or probiotics, can be of aid although some lack of solid evidence of efficacy.	Metronidazole	31-44	activation induced cytidine deaminase	Homo sapiens	94-97
32830674-2	2019	The crystal structure of metronidazole has been determined from high-resolution X-ray diffraction measurements at 90 K with a resolution of (sin theta/lambda)max = 1.12 A-1.	Metronidazole	25-38	embryonal Fyn-associated substrate	Homo sapiens	141-144
31543273-7	2019	RESULTS: Lipopolysaccharides elicited the production of proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha by macrophages, but this was suppressed by ciprofloxacin and metronidazole.	Metronidazole	194-207	interleukin 1 beta	Homo sapiens	82-132
32023219-7	2020	Metronidazole in Oral Mix and Oral Mix Sugar-Free oral suspensions, compounded from United States Pharmacopeia-grade powder or commercially available tablets, are a suitable alternative as an extemporaneously prepared medication.	Metronidazole	0-13	Mix paired-like homeobox	Homo sapiens	22-25
31810406-5	2021	Antibiotics were the class recording the widest diversity; metronidazole showed the lowest concentration (0.023 microg L-1) and sulfamethoxazole presented the highest concentration (1.374 microg L-1) in influent samples.	Metronidazole	59-72	immunoglobulin kappa variable 1-16	Homo sapiens	119-122
31875435-15	2019	The adjunctive benefits of systemic metronidazole and amoxicillin in non-surgical periodontal therapy are decreased serum IL-6 expression and normal carotid artery.	Metronidazole	36-49	interleukin 6	Rattus norvegicus	122-126
31347761-4	2019	Due to the existence of competitive absorption, Tb-MOF has a high selectivity for detecting Fe3+ , MnO4 - , 4-nirophenol and nitroimidazole (ronidazole, metronidazole, dimetridazole, ornidazole) in aqueous through luminescent quenching.	Metronidazole	153-166	lysine acetyltransferase 8	Homo sapiens	51-54
30679584-4	2019	Although treatment of BV by metronidazole vaginal tablets significantly increased the N subgroup in the MGP (p = 0.020), there was no significant improvement in the preterm delivery rate.	Metronidazole	28-41	matrix Gla protein	Homo sapiens	104-107
31463802-3	2019	The method has a linear response in the 0.06-15 mug mL-1 metronidazole concentration range and a 20 ng mL-1 detection limit.	Metronidazole	57-70	L1 cell adhesion molecule	Mus musculus	52-56
31359734-16	2019	The results showed that Fuyanshu Capsules combined with levofloxacin and metronidazole could alleviate the clinical symptoms and signs of chronic pelvic inflammation of damp-heat stagnation type,reduce the recurrence rate of pelvic inflammation,relieve pelvic pain,and alleviate the inflammation status of patients by regulating the expression of IL-10 and IL-1beta in peripheral serum.	Metronidazole	73-86	interleukin 10	Homo sapiens	347-352
31359734-16	2019	The results showed that Fuyanshu Capsules combined with levofloxacin and metronidazole could alleviate the clinical symptoms and signs of chronic pelvic inflammation of damp-heat stagnation type,reduce the recurrence rate of pelvic inflammation,relieve pelvic pain,and alleviate the inflammation status of patients by regulating the expression of IL-10 and IL-1beta in peripheral serum.	Metronidazole	73-86	interleukin 1 beta	Homo sapiens	357-365
30706508-0	2019	Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.	Metronidazole	11-24	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	42-48
30706508-3	2019	In vitro, CYP2A6 selectively forms 2-hydroxymetronidazole (2HM) from metronidazole (MTZ).	Metronidazole	44-57	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	10-16
30706508-3	2019	In vitro, CYP2A6 selectively forms 2-hydroxymetronidazole (2HM) from metronidazole (MTZ).	Metronidazole	84-87	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	10-16
30706508-4	2019	The purpose of this study was to evaluate MTZ as a CYP2A6 phenotyping probe drug in healthy adults against the well-established method of measuring trans-3-hydroxycotinine (3HC)/cotinine (COT).	Metronidazole	42-45	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	51-57
30706508-10	2019	CYP2A6 genotype had significant impacts on both MTZ and NIC phenotyping ratios with decreased activity predicted phenotypes demonstrating 2HM/MTZ ratios &lt;=58% and 3HC/COT ratios &lt;=56% compared with extensive activity predicted phenotypes at all time points examined in the study (P &lt; 0.05).	Metronidazole	48-51	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6
30706508-10	2019	CYP2A6 genotype had significant impacts on both MTZ and NIC phenotyping ratios with decreased activity predicted phenotypes demonstrating 2HM/MTZ ratios &lt;=58% and 3HC/COT ratios &lt;=56% compared with extensive activity predicted phenotypes at all time points examined in the study (P &lt; 0.05).	Metronidazole	142-145	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6
30706508-12	2019	CONCLUSIONS: Metronidazole via 2HM/MTZ performed well as a novel, safe phenotyping probe for CYP2A6 in healthy adults.	Metronidazole	13-26	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	93-99
31330131-4	2019	We used our previously developed in vivo zebrafish model of inducible podocyte-targeted injury and found that triptolide or the inhibition of p53 and gadd45ba with morpholino (MO) alleviated metronidazole (MTZ) induced edema in zebrafish, while the overexpression of gadd45ba in podocytes blocked the protective effect of triptolide and p53 MO on podocyte injury in zebrafish.	Metronidazole	191-204	tumor protein p53	Danio rerio	142-145
31330131-4	2019	We used our previously developed in vivo zebrafish model of inducible podocyte-targeted injury and found that triptolide or the inhibition of p53 and gadd45ba with morpholino (MO) alleviated metronidazole (MTZ) induced edema in zebrafish, while the overexpression of gadd45ba in podocytes blocked the protective effect of triptolide and p53 MO on podocyte injury in zebrafish.	Metronidazole	191-204	tumor protein p53	Danio rerio	337-340
31330131-4	2019	We used our previously developed in vivo zebrafish model of inducible podocyte-targeted injury and found that triptolide or the inhibition of p53 and gadd45ba with morpholino (MO) alleviated metronidazole (MTZ) induced edema in zebrafish, while the overexpression of gadd45ba in podocytes blocked the protective effect of triptolide and p53 MO on podocyte injury in zebrafish.	Metronidazole	206-209	tumor protein p53	Danio rerio	142-145
32454709-5	2019	MZ tablets of enhanced mechanical properties and fast disintegrating and dissolving rates were compressed from MCR.	Metronidazole	0-2	nuclear receptor subfamily 3 group C member 2	Homo sapiens	111-114
30575959-4	2019	The combination of hemoglobin and transferrin receptor defined IDA/NIDA.	Metronidazole	67-71	transferrin receptor	Homo sapiens	34-54
30515506-8	2018	To prove the concept, Au-NCs@GST was successfully applied to detect metronidazole (MNZ) both in solution and in living cells.	Metronidazole	68-81	glutathione S-transferase kappa 1	Homo sapiens	29-32
30403784-9	2019	Conclusions: Consequently, fluoroquinolones/metronidazole/clarithromycin-based triple therapies can be used to eradicate H. pylori infection, if one does not know the CYP2C19 genotype of the patient.	Metronidazole	44-57	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	167-174
30056227-7	2019	For the antibiotic Metronidazole, the highest removal value (127 mg/g) is expected to occur at the maximum levels attributed to each of the factors (pH = 8, Cin = 40 mg/L, T = 30  C).	Metronidazole	19-32	pyridoxal phosphatase	Homo sapiens	157-160
30515506-8	2018	To prove the concept, Au-NCs@GST was successfully applied to detect metronidazole (MNZ) both in solution and in living cells.	Metronidazole	83-86	glutathione S-transferase kappa 1	Homo sapiens	29-32
30058857-8	2018	After metronidazole administration, mean change in plasma cytokeratin-18 concentration from T1 to T2 was significantly lower with vehicle than with A muciniphila treatment (-0.27 vs 2.4 ng/mL).	Metronidazole	6-19	keratin 18	Canis lupus familiaris	58-72
30473741-10	2018	Metronidazole treatment in the experimental model showed an increase in LPO, TOS, and TOS/TAS and a decrease in CAT, SOD, GPx, and TAS.	Metronidazole	0-13	lactoperoxidase	Rattus norvegicus	72-75
30473741-10	2018	Metronidazole treatment in the experimental model showed an increase in LPO, TOS, and TOS/TAS and a decrease in CAT, SOD, GPx, and TAS.	Metronidazole	0-13	catalase	Rattus norvegicus	112-115
30473741-14	2018	An increase was observed in LPO, TOS, and TOS/TAS in both glands exposed to metronidazole.	Metronidazole	76-89	lactoperoxidase	Rattus norvegicus	28-31
30367827-5	2018	We found that clonazepam, flunitrazepam, flutamide, nilutamide, nimesulide, and nimetazepam were substantially reduced by recombinant AOX1 and HLC, whereas azelnidipine, nifedipine, and nimodipine were slightly reduced and metronidazole and tolcapone were not reduced.	Metronidazole	223-236	aldehyde oxidase 1	Homo sapiens	134-138
30146006-6	2018	Further study showed that metronidazole- and vancomycin-sensitive bacteria are involved in maintenance of NLRP3/IL-1beta signal in pMphi.	Metronidazole	26-39	NLR family, pyrin domain containing 3	Mus musculus	106-111
30146006-6	2018	Further study showed that metronidazole- and vancomycin-sensitive bacteria are involved in maintenance of NLRP3/IL-1beta signal in pMphi.	Metronidazole	26-39	interleukin 1 alpha	Mus musculus	112-120
30115857-4	2018	In the gastrocnemius muscle, metronidazole causes upregulation of Hdac4, myogenin, MuRF1, and atrogin1, which are implicated in skeletal muscle neurogenic atrophy.	Metronidazole	29-42	histone deacetylase 4	Mus musculus	66-71
30115857-4	2018	In the gastrocnemius muscle, metronidazole causes upregulation of Hdac4, myogenin, MuRF1, and atrogin1, which are implicated in skeletal muscle neurogenic atrophy.	Metronidazole	29-42	myogenin	Mus musculus	73-81
30115857-4	2018	In the gastrocnemius muscle, metronidazole causes upregulation of Hdac4, myogenin, MuRF1, and atrogin1, which are implicated in skeletal muscle neurogenic atrophy.	Metronidazole	29-42	tripartite motif-containing 63	Mus musculus	83-88
30115857-4	2018	In the gastrocnemius muscle, metronidazole causes upregulation of Hdac4, myogenin, MuRF1, and atrogin1, which are implicated in skeletal muscle neurogenic atrophy.	Metronidazole	29-42	F-box protein 32	Mus musculus	94-102
30115857-5	2018	Metronidazole in SPF mice also upregulates skeletal muscle FoxO3, described as involved in apoptosis and muscle regeneration.	Metronidazole	0-13	forkhead box O3	Mus musculus	59-64
30115857-7	2018	PPARgamma and one of its important target genes, adiponectin, are also upregulated by metronidazole.	Metronidazole	86-99	peroxisome proliferator activated receptor gamma	Mus musculus	0-9
30115857-7	2018	PPARgamma and one of its important target genes, adiponectin, are also upregulated by metronidazole.	Metronidazole	86-99	adiponectin, C1Q and collagen domain containing	Mus musculus	49-60
30115857-8	2018	Metronidazole in germ-free (GF) mice increases the expression of other core clock genes, such as Bmal1 and Per2, as well as the metabolic regulators FoxO1 and Pdk4, suggesting a microbiota-independent pharmacologic effect.	Metronidazole	0-13	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	97-102
30115857-8	2018	Metronidazole in germ-free (GF) mice increases the expression of other core clock genes, such as Bmal1 and Per2, as well as the metabolic regulators FoxO1 and Pdk4, suggesting a microbiota-independent pharmacologic effect.	Metronidazole	0-13	period circadian clock 2	Mus musculus	107-111
30115857-8	2018	Metronidazole in germ-free (GF) mice increases the expression of other core clock genes, such as Bmal1 and Per2, as well as the metabolic regulators FoxO1 and Pdk4, suggesting a microbiota-independent pharmacologic effect.	Metronidazole	0-13	forkhead box O1	Mus musculus	149-154
30115857-8	2018	Metronidazole in germ-free (GF) mice increases the expression of other core clock genes, such as Bmal1 and Per2, as well as the metabolic regulators FoxO1 and Pdk4, suggesting a microbiota-independent pharmacologic effect.	Metronidazole	0-13	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	159-163
29785241-10	2018	At high doses of MTZ, caspase 3 was rapidly cleaved, beta-cells underwent regulated cell death, and macrophages were recruited to the islet to phagocytose the debris.	Metronidazole	17-20	caspase 3, apoptosis-related cysteine peptidase a	Danio rerio	22-31
30182050-10	2018	In the long term, the vancomycin/metronidazole-induced lasting increase in PA aggravated colitis development in IL10-/- mice.	Metronidazole	33-46	interleukin 10	Mus musculus	112-116
29493484-7	2018	Underlying dialysis, fever &gt;38.3  C, low median serum albumin levels and concomitant use of antibiotics were independent predictors of treatment failure in patients with CDI receiving metronidazole therapy.	Metronidazole	187-200	albumin	Homo sapiens	57-64
29307856-5	2018	Our data revealed that nitrofurantoin, sulfadiazine and metronidazole significantly inhibited the transport activity of OAT3 (IC50 values of 6.23+-1.33muM, 6.65+-1.30muM and 6.51+-0.99muM; Ki values of 5.86muM, 3.98muM and 6.48muM, respectively).	Metronidazole	56-69	solute carrier family 22 member 8	Homo sapiens	120-124
29734026-5	2018	Metronidazole was detected in all the samples with concentrations ranging from 0.05 to 13.51 ng L-1.	Metronidazole	0-13	L1 cell adhesion molecule	Homo sapiens	96-99
29955244-0	2018	Spin-Lattice Relaxation of Hyperpolarized Metronidazole in Signal Amplification by Reversible Exchange in Micro-Tesla Fields.	Metronidazole	42-55	spindlin 1	Homo sapiens	0-4
29307856-8	2018	In summary, our study is the first to show that nitrofurantoin, sulfadiazine and metronidazole are potent inhibitors of OAT3 and trimethoprim is a novel inhibitor of OATP1A2.	Metronidazole	81-94	solute carrier family 22 member 8	Homo sapiens	120-124
29307856-8	2018	In summary, our study is the first to show that nitrofurantoin, sulfadiazine and metronidazole are potent inhibitors of OAT3 and trimethoprim is a novel inhibitor of OATP1A2.	Metronidazole	81-94	solute carrier organic anion transporter family member 1A2	Homo sapiens	166-173
29955244-4	2018	Here, we report on a systematic study of 1H, 13C and 15N spin-lattice relaxation (T1) of metronidazole-13C2-15N2 in SABRE-SHEATH hyperpolarization process.	Metronidazole	89-102	spindlin 1	Homo sapiens	57-61
29452847-8	2018	No statically significant relationship was found between vagA and cagA genotypes and antibiotic resistance results (p&gt;0.5) except for the metronidazole, which had relation with the presence of cagA genotype (p=0.001).	Metronidazole	141-154	S100 calcium binding protein A8	Homo sapiens	196-200
29546300-7	2018	At 32 wk of gestation, serum hepcidin performed better than soluble transferrin receptor (sTfR) in identifying women with NIDA compared with the rest of the cohort (AUCs: 0.75 and 0.70, respectively) and in identifying women with NIDA among women with anemia (0.73 and 0.72, respectively).	Metronidazole	122-126	hepcidin antimicrobial peptide	Homo sapiens	29-37
29546300-7	2018	At 32 wk of gestation, serum hepcidin performed better than soluble transferrin receptor (sTfR) in identifying women with NIDA compared with the rest of the cohort (AUCs: 0.75 and 0.70, respectively) and in identifying women with NIDA among women with anemia (0.73 and 0.72, respectively).	Metronidazole	230-234	hepcidin antimicrobial peptide	Homo sapiens	29-37
29546300-10	2018	Conclusions: Hepcidin performed better than sTfR in identifying pregnant women with NIDA, but its cost may limit its use.	Metronidazole	84-88	hepcidin antimicrobial peptide	Homo sapiens	13-21
28204842-11	2017	Within the limits of the study, it can be stated that nonsurgical periodontal therapy with additional systemic administration of Amoxicillin and Metronidazole increases the level of HNP1-3 in GCF.	Metronidazole	145-158	HNP1	Homo sapiens	182-186
28667114-8	2017	Remarkably, this single commensal bacterium in the context of a complex population led to variations in host responses to metronidazole treatment, including increased expression of antimicrobial peptides Reg3beta and Reg3gamma and intestinal inflammation indicated by tumor necrosis factor alpha levels.	Metronidazole	122-135	regenerating islet-derived 3 beta	Mus musculus	204-212
28667114-8	2017	Remarkably, this single commensal bacterium in the context of a complex population led to variations in host responses to metronidazole treatment, including increased expression of antimicrobial peptides Reg3beta and Reg3gamma and intestinal inflammation indicated by tumor necrosis factor alpha levels.	Metronidazole	122-135	regenerating islet-derived 3 gamma	Mus musculus	217-226
27899252-0	2017	The effects of metronidazole on Cytochrome P450 Activity and Expression in rats after acute exposure to high altitude of 4300m.	Metronidazole	15-28	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	32-47
28218496-9	2017	PDLLA, in general, successfully retains additional elements, such as osteoconductive growth factors (BMP-2) and anti-infective agents, which was demonstrated using metronidazole, and thus prevents the systemic application of excessive doses.	Metronidazole	164-177	bone morphogenetic protein 2	Homo sapiens	101-106
28110684-5	2017	Finally, the obtained Pt-NCs@PEI are used to determine trace amount of metronidazole (MTZ) in buffer solution in showing a linear response over a concentration range of 0.25-300 muM and a low detection limit of 0.1 muM.	Metronidazole	71-84	latexin	Homo sapiens	178-181
28110684-5	2017	Finally, the obtained Pt-NCs@PEI are used to determine trace amount of metronidazole (MTZ) in buffer solution in showing a linear response over a concentration range of 0.25-300 muM and a low detection limit of 0.1 muM.	Metronidazole	71-84	latexin	Homo sapiens	215-218
28110684-5	2017	Finally, the obtained Pt-NCs@PEI are used to determine trace amount of metronidazole (MTZ) in buffer solution in showing a linear response over a concentration range of 0.25-300 muM and a low detection limit of 0.1 muM.	Metronidazole	86-89	latexin	Homo sapiens	178-181
28110684-5	2017	Finally, the obtained Pt-NCs@PEI are used to determine trace amount of metronidazole (MTZ) in buffer solution in showing a linear response over a concentration range of 0.25-300 muM and a low detection limit of 0.1 muM.	Metronidazole	86-89	latexin	Homo sapiens	215-218
27793493-7	2016	Metronidazole or clindamycin is effective to treat BV (EL3).	Metronidazole	0-13	spectrin beta, erythrocytic	Homo sapiens	55-58
27801837-0	2016	Human Lysozyme Synergistically Enhances Bactericidal Dynamics and Lowers the Resistant Mutant Prevention Concentration for Metronidazole to Helicobacter pylori by Increasing Cell Permeability.	Metronidazole	123-136	lysozyme	Homo sapiens	6-14
27115499-9	2016	Finally, a marginally significant association between absence of cpb2 and decreased susceptibility to metronidazole (MIC &gt;= 16 mug ml-1) was detected.	Metronidazole	102-115	cpb2	Clostridium perfringens	65-69
27149989-11	2016	Ablation of a substantial portion of nitroreductase-expressing pax7b cells with metronidazole prior to wounding triggered rapid pax7a-only cell accumulation, but this neither inhibited nor augmented pax7a-only cell-derived myogenesis and thus altered the cellular repair dynamics during wound healing.	Metronidazole	80-93	paired box 7b	Danio rerio	63-68
27236016-7	2016	Several of the new compounds exhibited potent activity against G. lamblia strains, including metronidazole-resistant strains of G. lamblia (EC50 = 0.1-2.5 muM cf.	Metronidazole	93-106	latexin	Homo sapiens	155-158
27236016-8	2016	metronidazole EC50 = 6.1-18 muM).	Metronidazole	0-13	latexin	Homo sapiens	28-31
27149989-11	2016	Ablation of a substantial portion of nitroreductase-expressing pax7b cells with metronidazole prior to wounding triggered rapid pax7a-only cell accumulation, but this neither inhibited nor augmented pax7a-only cell-derived myogenesis and thus altered the cellular repair dynamics during wound healing.	Metronidazole	80-93	paired box 7a	Danio rerio	128-133
27845497-7	2016	The co-administration of rhLys and clindamycin or metronidazole improved both antibiotics" efficiency and lysozyme-driven biofilm degradation.	Metronidazole	50-63	lysozyme	Homo sapiens	106-114
27845497-9	2016	This suggests that human lysozyme could be added as an anti-biofilm cotreatment to vaginal antibiotherapy, preferably metronidazole, against Gardnerella vaginalis infection in vivo.	Metronidazole	118-131	lysozyme	Homo sapiens	25-33
26792065-4	2016	Using a number of transgenic zebrafish models, we showed that moderate elevation of Rac1 activity in podocytes did not impair the glomerular filtration barrier but aggravated metronidazole-induced podocyte injury, while inhibition of Rac1 activity ameliorated metronidazole-induced podocyte injury.	Metronidazole	175-188	Rac family small GTPase 1a	Danio rerio	84-88
26792065-4	2016	Using a number of transgenic zebrafish models, we showed that moderate elevation of Rac1 activity in podocytes did not impair the glomerular filtration barrier but aggravated metronidazole-induced podocyte injury, while inhibition of Rac1 activity ameliorated metronidazole-induced podocyte injury.	Metronidazole	260-273	Rac family small GTPase 1a	Danio rerio	84-88
26118896-3	2015	Administration of the pro-drug metronidazole (Mtz) resulted in activation of caspase 3 in CFP-positive neurons and in a reduction in dat-positive cells by 5 days post-fertilization (dpf).	Metronidazole	31-44	complement factor properdin	Danio rerio	90-93
26928597-9	2016	CONCLUSION: Adjunctive systemic amoxicillin and metronidazole medication to SRP significantly improved the clinical outcomes with respect to mean PD, CAL and BOP compared to SRP alone.	Metronidazole	48-61	BOP	Homo sapiens	158-161
26118896-3	2015	Administration of the pro-drug metronidazole (Mtz) resulted in activation of caspase 3 in CFP-positive neurons and in a reduction in dat-positive cells by 5 days post-fertilization (dpf).	Metronidazole	31-44	caspase 3, apoptosis-related cysteine peptidase a	Danio rerio	77-86
26118896-3	2015	Administration of the pro-drug metronidazole (Mtz) resulted in activation of caspase 3 in CFP-positive neurons and in a reduction in dat-positive cells by 5 days post-fertilization (dpf).	Metronidazole	46-49	caspase 3, apoptosis-related cysteine peptidase a	Danio rerio	77-86
26118896-3	2015	Administration of the pro-drug metronidazole (Mtz) resulted in activation of caspase 3 in CFP-positive neurons and in a reduction in dat-positive cells by 5 days post-fertilization (dpf).	Metronidazole	46-49	complement factor properdin	Danio rerio	90-93
26304821-7	2015	We recommend that a diagnosis of CS be considered an absolute contraindication to the use of metronidazole.	Metronidazole	93-106	citrate synthase	Homo sapiens	33-35
26277566-0	2015	Metronidazole-but not IL-10 or prednisolone-rescues Trichuris muris infected C57BL/6 IL-10 deficient mice from severe disease.	Metronidazole	0-13	interleukin 10	Mus musculus	85-90
26378046-11	2015	Additionally, UDCA plus MTZ (MD -544.66, P &lt; 0.001) showed a significant reduction in ALP levels compared with OBS, but appeared to be associated with more AEs compared with UDCA (OR 5.09), UDCA plus MMF (OR 4.80) or OBS (OR 7.21).	Metronidazole	24-27	alkaline phosphatase, placental	Homo sapiens	89-92
26092845-8	2015	In metronidazole-treated myl7:nitroreductase embryos, myocardial cells were targeted for apoptosis, which resulted in the loss of endocardial nfatc1 expression.	Metronidazole	3-16	nuclear factor of activated T cells 1	Danio rerio	142-148
26053779-4	2015	Metronidazole and fluconazole inhibit the metabolism of warfarin by blocking cytochrome P-450 2C9 (CYP-2C9), the major metabolic pathway of warfarin, with the end result being dramatic increases in patients" international normalized ratios (INRs) and potentially fatal bleeding.	Metronidazole	0-13	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	77-97
26053779-4	2015	Metronidazole and fluconazole inhibit the metabolism of warfarin by blocking cytochrome P-450 2C9 (CYP-2C9), the major metabolic pathway of warfarin, with the end result being dramatic increases in patients" international normalized ratios (INRs) and potentially fatal bleeding.	Metronidazole	0-13	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	99-106
25470432-0	2015	Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes.	Metronidazole	0-13	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
26007680-0	2015	Effect of nonsurgical periodontal treatment in conjunction with either systemic administration of amoxicillin and metronidazole or additional photodynamic therapy on the concentration of matrix metalloproteinases 8 and 9 in gingival crevicular fluid in patients with aggressive periodontitis.	Metronidazole	114-127	matrix metallopeptidase 8	Homo sapiens	187-220
26007680-11	2015	CONCLUSIONS: Within the limits of the present study, it may be suggested that in patients with AgP, nonsurgical periodontal therapy in conjunction with adjunctive systemic administration of amoxicilin and metronidazole is more effective in reducing GCF MMP-8 levels compared to the adjunctive use of PDT.	Metronidazole	205-218	matrix metallopeptidase 8	Homo sapiens	253-258
25470432-8	2015	In both cells, the expressions of CYP2C8, CYP2C9, CYP3A4 and constitutive androstane receptor (CAR) were decreased by MTZ treatment.	Metronidazole	118-121	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	34-40
25470432-8	2015	In both cells, the expressions of CYP2C8, CYP2C9, CYP3A4 and constitutive androstane receptor (CAR) were decreased by MTZ treatment.	Metronidazole	118-121	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	42-48
25470432-8	2015	In both cells, the expressions of CYP2C8, CYP2C9, CYP3A4 and constitutive androstane receptor (CAR) were decreased by MTZ treatment.	Metronidazole	118-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
25470432-8	2015	In both cells, the expressions of CYP2C8, CYP2C9, CYP3A4 and constitutive androstane receptor (CAR) were decreased by MTZ treatment.	Metronidazole	118-121	nuclear receptor subfamily 1 group I member 3	Homo sapiens	61-93
25470432-8	2015	In both cells, the expressions of CYP2C8, CYP2C9, CYP3A4 and constitutive androstane receptor (CAR) were decreased by MTZ treatment.	Metronidazole	118-121	nuclear receptor subfamily 1 group I member 3	Homo sapiens	95-98
25470432-11	2015	Our findings suggest that the interaction between MTZ and S-warfarin may be due to the MTZ-induced down-regulation of CYP2C9, the primary enzyme responsible for S-warfarin hydroxylation, and CAR, which regulates CYP2C9 expression.	Metronidazole	50-53	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	118-124
25470432-11	2015	Our findings suggest that the interaction between MTZ and S-warfarin may be due to the MTZ-induced down-regulation of CYP2C9, the primary enzyme responsible for S-warfarin hydroxylation, and CAR, which regulates CYP2C9 expression.	Metronidazole	50-53	nuclear receptor subfamily 1 group I member 3	Homo sapiens	191-194
25470432-11	2015	Our findings suggest that the interaction between MTZ and S-warfarin may be due to the MTZ-induced down-regulation of CYP2C9, the primary enzyme responsible for S-warfarin hydroxylation, and CAR, which regulates CYP2C9 expression.	Metronidazole	50-53	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	212-218
25470432-11	2015	Our findings suggest that the interaction between MTZ and S-warfarin may be due to the MTZ-induced down-regulation of CYP2C9, the primary enzyme responsible for S-warfarin hydroxylation, and CAR, which regulates CYP2C9 expression.	Metronidazole	87-90	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	118-124
25470432-11	2015	Our findings suggest that the interaction between MTZ and S-warfarin may be due to the MTZ-induced down-regulation of CYP2C9, the primary enzyme responsible for S-warfarin hydroxylation, and CAR, which regulates CYP2C9 expression.	Metronidazole	87-90	nuclear receptor subfamily 1 group I member 3	Homo sapiens	191-194
25470432-11	2015	Our findings suggest that the interaction between MTZ and S-warfarin may be due to the MTZ-induced down-regulation of CYP2C9, the primary enzyme responsible for S-warfarin hydroxylation, and CAR, which regulates CYP2C9 expression.	Metronidazole	87-90	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	212-218
25470432-12	2015	We also found that MTZ use may alter the disposition of drugs metabolized by the CYP isozymes investigated.	Metronidazole	19-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84
23794105-11	2013	Albendazole and coenzyme B12 were the most promising compounds to boost the efficacy of metronidazole.	Metronidazole	88-101	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	25-28
24907628-0	2015	Effects of metronidazole on proopiomelanocortin a gene expression in zebrafish.	Metronidazole	11-24	proopiomelanocortin a	Danio rerio	28-49
24907628-3	2015	In current study, we found that MTZ can induce proopiomelanocortin a (pomca) expression in zebrafish larvae.	Metronidazole	32-35	proopiomelanocortin a	Danio rerio	47-68
24907628-6	2015	Furthermore, up-regulated levels of prolactin (prl) and glycoprotein hormone subunit alpha (gsualpha) were also observed after the MTZ treatment.	Metronidazole	131-134	prolactin	Danio rerio	36-45
25713485-0	2015	Impact of metronidazole and amoxicillin combination on matrix metalloproteinases-1 and tissue inhibitors of matrix metalloproteinases balance in generalized aggressive periodontitis.	Metronidazole	10-23	matrix metallopeptidase 1	Homo sapiens	55-82
25713485-2	2015	We hypothesized that better clinical healing of adjunctive use of amoxicillin plus metronidazole combination may be related to the effect of this combination therapy to restore imbalance between matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) which is associated with connective tissue and alveolar bone destruction in patients with GAgP.	Metronidazole	83-96	matrix metallopeptidase 1	Homo sapiens	222-225
25713485-2	2015	We hypothesized that better clinical healing of adjunctive use of amoxicillin plus metronidazole combination may be related to the effect of this combination therapy to restore imbalance between matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) which is associated with connective tissue and alveolar bone destruction in patients with GAgP.	Metronidazole	83-96	TIMP metallopeptidase inhibitor 1	Homo sapiens	256-260
25713485-13	2015	CONCLUSION: The results of this study suggest that metronidazole and amoxicillin combination as an adjunct to SRP results in better clinical healing through restoring TIMP-1/MMP-1 balance.	Metronidazole	51-64	TIMP metallopeptidase inhibitor 1	Homo sapiens	167-173
25713485-13	2015	CONCLUSION: The results of this study suggest that metronidazole and amoxicillin combination as an adjunct to SRP results in better clinical healing through restoring TIMP-1/MMP-1 balance.	Metronidazole	51-64	matrix metallopeptidase 1	Homo sapiens	174-179
24633026-2	2014	We treated a total of 28 patients allergic to penicillin with a proton pump inhibitor (PPI), metronidazole (250 mg bid) and sitafloxacin (100 mg bid) for one to two weeks.	Metronidazole	93-106	BH3 interacting domain death agonist	Homo sapiens	115-118
25318626-4	2014	We examined the relationship between metronidazole exposure and urinary I-FABP concentrations in premature infants with suspected intra-abdominal infection.	Metronidazole	37-50	fatty acid binding protein 2	Homo sapiens	72-78
25318626-6	2014	We analyzed the relationship between I-FABP concentrations and measures of metronidazole exposure and pharmacokinetics, maturational factors, and other covariates.	Metronidazole	75-88	fatty acid binding protein 2	Homo sapiens	37-43
25318626-9	2014	However, when the sample was limited to premature infants with necrotic gastrointestinal disease, an association was found between average predicted metronidazole concentration and I-FABP concentration (p = 0.006).	Metronidazole	149-162	fatty acid binding protein 2	Homo sapiens	181-187
25318626-10	2014	CONCLUSION: While a predictive association between urinary I-FABP and metronidazole systemic exposure was not observed, the data suggest the potential of this endogenous biomarker to serve as a pharmacodynamic surrogate for antimicrobial treatment of serious abdominal infections in neonates and infants.	Metronidazole	70-83	fatty acid binding protein 2	Homo sapiens	59-65
25695169-9	2015	More NAP1 cases had a change in treatment from metronidazole to oral vancomycin plus intravenous metronidazole (P=.01).	Metronidazole	47-60	nucleosome assembly protein 1 like 1	Homo sapiens	5-9
25695169-9	2015	More NAP1 cases had a change in treatment from metronidazole to oral vancomycin plus intravenous metronidazole (P=.01).	Metronidazole	97-110	nucleosome assembly protein 1 like 1	Homo sapiens	5-9
25826490-4	2015	However, effects of the combination of metronidazole with amoxicillin or spiramycin on the release and activation of MMP-2 and the balance MMP-2/TIMP-2 were rarely studied.	Metronidazole	39-52	matrix metallopeptidase 2	Homo sapiens	117-122
26366345-8	2015	CT 14 days after starting MTZ showed no change in the intra-abdominal tumor, and resection of the tumor was therefore performed.	Metronidazole	26-29	sarcoma antigen 1	Homo sapiens	0-5
25527642-8	2014	Treatment of zebrafish larvae Tg(mbp:nfsB-egfp) with metronidazole (Mtz) resulted in the selective ablation of oligodendrocytes and led to demyelination, accompanied by behavioral changes, including decreased total movement distance, velocity, total movement time and fast movement time.	Metronidazole	53-66	myelin basic protein a	Danio rerio	33-36
25527642-8	2014	Treatment of zebrafish larvae Tg(mbp:nfsB-egfp) with metronidazole (Mtz) resulted in the selective ablation of oligodendrocytes and led to demyelination, accompanied by behavioral changes, including decreased total movement distance, velocity, total movement time and fast movement time.	Metronidazole	68-71	myelin basic protein a	Danio rerio	33-36
25527642-9	2014	After withdrawal of Mtz for a seven day recovery period, the expression of EGFP and MBP protein was observed again which indicates remyelination.	Metronidazole	20-23	myelin basic protein a	Danio rerio	84-87
24827414-9	2014	Pathogenicity genes cagA, dupA, and vacA s1a/m1 were detected frequently in isolates which were also found to be resistant to MTZ, CLR, and AML.	Metronidazole	126-129	S100 calcium binding protein A8	Homo sapiens	20-24
25068305-10	2014	After metronidazole therapy 7/11 (63.3%) reduced CH4 production and they showed a mean HbA1c significantly lower than corresponding value before antibiotic therapy (7.63 +- 0.7% vs. 8.25 +- 0.8%).	Metronidazole	6-19	hemoglobin subunit alpha 1	Homo sapiens	87-91
25101989-8	2014	Metronidazole seemed to decrease CRP but was ineffective in ameliorating diarrhea.	Metronidazole	0-13	C-reactive protein	Homo sapiens	33-36
24617056-3	2013	The result showed that metronidazole could be effectively removed using Ti/SnO2-Sb-Ce.	Metronidazole	23-36	strawberry notch homolog 2	Homo sapiens	75-78
23813797-4	2013	Although several cDNA-expressed P450 enzymes catalyzed 2-hydroxymetronidazole formation at a supratherapeutic concentration of metronidazole (2000 muM), at a "therapeutic concentration" of 100 muM only CYPs 2A6, 3A4, 3A5, and 3A7 catalyzed metronidazole 2-hydroxylation at rates substantially greater than control vector, and CYP2A6 catalyzed 2-hydroxymetronidazole formation at rates 6-fold higher than the next most active enzyme.	Metronidazole	64-77	latexin	Homo sapiens	147-150
23813797-4	2013	Although several cDNA-expressed P450 enzymes catalyzed 2-hydroxymetronidazole formation at a supratherapeutic concentration of metronidazole (2000 muM), at a "therapeutic concentration" of 100 muM only CYPs 2A6, 3A4, 3A5, and 3A7 catalyzed metronidazole 2-hydroxylation at rates substantially greater than control vector, and CYP2A6 catalyzed 2-hydroxymetronidazole formation at rates 6-fold higher than the next most active enzyme.	Metronidazole	127-140	latexin	Homo sapiens	147-150
23813797-7	2013	Selective chemical inhibitors of CYP2A6 inhibited metronidazole 2-hydroxylation in a concentration-dependent manner and inhibitory antibodies against CYP2A6 virtually eliminated metronidazole 2-hydroxylation (&gt;99%).	Metronidazole	50-63	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	33-39
23813797-7	2013	Selective chemical inhibitors of CYP2A6 inhibited metronidazole 2-hydroxylation in a concentration-dependent manner and inhibitory antibodies against CYP2A6 virtually eliminated metronidazole 2-hydroxylation (&gt;99%).	Metronidazole	178-191	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	150-156
23813797-9	2013	These results suggest that CYP2A6 is the primary catalyst responsible for the 2-hydroxylation of metronidazole, a reaction that may function as a marker of CYP2A6 activity both in vitro and in vivo.	Metronidazole	97-110	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	27-33
23813797-9	2013	These results suggest that CYP2A6 is the primary catalyst responsible for the 2-hydroxylation of metronidazole, a reaction that may function as a marker of CYP2A6 activity both in vitro and in vivo.	Metronidazole	97-110	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	156-162
23807048-6	2013	In this transgenic system, bacterial nitroreductase enzyme (NTR), which converts the prodrug metronidazole (Mtz) into a cytotoxic DNA cross-linking agent, is expressed in oligodendrocyte lineage cells under the control of the mbp and sox10 promoter.	Metronidazole	108-111	myelin basic protein a	Danio rerio	226-229
23807048-6	2013	In this transgenic system, bacterial nitroreductase enzyme (NTR), which converts the prodrug metronidazole (Mtz) into a cytotoxic DNA cross-linking agent, is expressed in oligodendrocyte lineage cells under the control of the mbp and sox10 promoter.	Metronidazole	108-111	SRY-box transcription factor 10	Danio rerio	234-239
23466998-5	2013	Treatment of these transgenic zebrafish with metronidazole results in podocyte apoptosis, a loss of nephrin and podocin expression, foot process effacement, and a leaky glomerular filtration barrier.	Metronidazole	45-58	NPHS1 adhesion molecule, nephrin	Danio rerio	100-107
23602170-0	2013	Controlled release of metronidazole from composite poly-epsilon-caprolactone/alginate (PCL/alginate) rings for dental implants.	Metronidazole	22-35	PHD finger protein 1	Homo sapiens	87-90
23466998-5	2013	Treatment of these transgenic zebrafish with metronidazole results in podocyte apoptosis, a loss of nephrin and podocin expression, foot process effacement, and a leaky glomerular filtration barrier.	Metronidazole	45-58	NPHS2 stomatin family member, podocin	Danio rerio	112-119
23199846-9	2013	We believe that the association C3G+aminoglycoside+metronidazole should be used first-line in the pediatric peritonitis in our context.	Metronidazole	51-64	Rap guanine nucleotide exchange factor 1	Homo sapiens	32-35
23142570-2	2013	All samples had anti-T. vaginalis activity; however, HP1 demonstrated the best selectivity against this protozoan (metronidazole-resistant and susceptible isolates), with no cytotoxicity on mammalian cells (selectivity index of 73.97).	Metronidazole	115-128	defensin alpha 1	Homo sapiens	53-56
23142570-3	2013	Moreover, HP1 had activity against a metronidazole-resistant isolate (52% of viable trophozoites), and this effect was higher when tested with a low concentration of metronidazole (23% of viable trophozoites).	Metronidazole	37-50	defensin alpha 1	Homo sapiens	10-13
23142570-3	2013	Moreover, HP1 had activity against a metronidazole-resistant isolate (52% of viable trophozoites), and this effect was higher when tested with a low concentration of metronidazole (23% of viable trophozoites).	Metronidazole	166-179	defensin alpha 1	Homo sapiens	10-13
23142570-5	2013	Therefore, the analyzed molecules are promising prototypes for new antiprotozoal drugs, especially HP1, which seems to improve metronidazole"s effect on a resistant T. vaginalis isolate.	Metronidazole	127-140	defensin alpha 1	Homo sapiens	99-102
23597911-3	2013	The cyclic voltammetry investigations reveal that the peak current of metronidazole reduction at the cysteic acid/PDDA-GN/GCE was remarkably enhanced compared to the bare GCE, the cysteic acid/GCE and the PDDA-GN/GCE.	Metronidazole	70-83	aminomethyltransferase	Homo sapiens	114-125
23597911-3	2013	The cyclic voltammetry investigations reveal that the peak current of metronidazole reduction at the cysteic acid/PDDA-GN/GCE was remarkably enhanced compared to the bare GCE, the cysteic acid/GCE and the PDDA-GN/GCE.	Metronidazole	70-83	aminomethyltransferase	Homo sapiens	122-125
23597911-3	2013	The cyclic voltammetry investigations reveal that the peak current of metronidazole reduction at the cysteic acid/PDDA-GN/GCE was remarkably enhanced compared to the bare GCE, the cysteic acid/GCE and the PDDA-GN/GCE.	Metronidazole	70-83	aminomethyltransferase	Homo sapiens	171-174
23597911-3	2013	The cyclic voltammetry investigations reveal that the peak current of metronidazole reduction at the cysteic acid/PDDA-GN/GCE was remarkably enhanced compared to the bare GCE, the cysteic acid/GCE and the PDDA-GN/GCE.	Metronidazole	70-83	aminomethyltransferase	Homo sapiens	205-216
23597911-5	2013	The fabricated sensor shows linear response to metronidazole in the ranges of 10 nM-1 muM and 70 muM-800 muM, with a detection limit of 2.3 nM (S/N=3).	Metronidazole	47-60	latexin	Homo sapiens	86-89
23597911-5	2013	The fabricated sensor shows linear response to metronidazole in the ranges of 10 nM-1 muM and 70 muM-800 muM, with a detection limit of 2.3 nM (S/N=3).	Metronidazole	47-60	latexin	Homo sapiens	97-100
23597911-5	2013	The fabricated sensor shows linear response to metronidazole in the ranges of 10 nM-1 muM and 70 muM-800 muM, with a detection limit of 2.3 nM (S/N=3).	Metronidazole	47-60	latexin	Homo sapiens	97-100
22940251-7	2012	Thermoresponsive release of metronidazole was observed from s-IPN composed of p(NIPAA)/PCL at 37 C but not from p(NIPAA-co-HEMA)/PCL at this temperature.	Metronidazole	28-41	PHD finger protein 1	Homo sapiens	87-90
23142353-5	2012	Ofloxacine+metronidazole association can be proposed in first intention (EL1).	Metronidazole	11-24	erythrocyte membrane protein band 4.1	Homo sapiens	73-76
22444681-2	2012	All the compounds were capable of inhibiting the growth of E. histolytica out of which four compounds (IC(50)=0.28-1.38 muM) were found to have better efficacy than the standard drug Metronidazole (IC(50)=1.8 muM).	Metronidazole	183-196	latexin	Homo sapiens	120-123
21930763-9	2011	ST-7 (B), a metronidazole-resistant isolate, was found to be more sensitive to nitrosative stress.	Metronidazole	12-25	suppression of tumorigenicity 7	Homo sapiens	0-4
22733075-7	2012	MBX-500 displayed potency across nearly 50 isolates, including those of the fluoroquinolone-resistant, toxin-overproducing NAP1/027 ribotype, performing as well as comparator antibiotics vancomycin and metronidazole.	Metronidazole	202-215	diencephalon/mesencephalon homeobox 1	Mus musculus	0-3
22440901-3	2012	In this study, we generated an inducible model of podocyte injury in zebrafish (pod::NTR-mCherry) by expressing a bacterial nitroreductase, which converts metronidazole to a cytotoxin, specifically in podocytes under the control of the zebrafish nphs2/podocin promoter.	Metronidazole	155-168	NPHS2 stomatin family member, podocin	Danio rerio	246-251
22440901-3	2012	In this study, we generated an inducible model of podocyte injury in zebrafish (pod::NTR-mCherry) by expressing a bacterial nitroreductase, which converts metronidazole to a cytotoxin, specifically in podocytes under the control of the zebrafish nphs2/podocin promoter.	Metronidazole	155-168	NPHS2 stomatin family member, podocin	Danio rerio	252-259
22719259-7	2012	We found that the metronidazole, not an anti-pseudomonal antibiotic given to the first patient infected with S-Pae, triggered the SOS response that subsequently activated the integrase IntI1 expression.	Metronidazole	18-31	xylosyltransferase 2	Homo sapiens	130-133
21920766-1	2011	A series of novel metronidazole derivatives were recently reported as potent anticancer agents targeting EGFR and HER-2 by our group [Qian, Y.; Zhang, H. J.; Zhang, H.; Xu, C.; Zhao, J.; Zhu, H. L. Bioorg.	Metronidazole	18-31	epidermal growth factor receptor	Mus musculus	105-109
21920766-1	2011	A series of novel metronidazole derivatives were recently reported as potent anticancer agents targeting EGFR and HER-2 by our group [Qian, Y.; Zhang, H. J.; Zhang, H.; Xu, C.; Zhao, J.; Zhu, H. L. Bioorg.	Metronidazole	18-31	erb-b2 receptor tyrosine kinase 2	Mus musculus	114-119
21736711-8	2011	Metronidazole (89%) and ciprofloxacin (86%) were commonly given for diarrhea and UTI, respectively, whereas amoxicillin/clavulanate was dispensed (51%) for the other simulated cases.	Metronidazole	0-13	alpha-1-microglobulin/bikunin precursor	Homo sapiens	81-84